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SUMMARY 
 
During these three years, my PhD studies evaluated the role of the cross-talk between glia 
and neurons in physiological and/or pathological conditions, paying attention to 
neuroinflammatory processes in neuropsychiatric disorders, mainly in Alzheimer’s disease (AD). 
Glia is a cell population highly present in the central nervous system (CNS) with the 
purpose, among other functions, to support neurons. In fact, many of these cells are closely in 
contact with neurons, actively participating to homeostatic support and synaptic transmission. For 
instance, astrocytes are considered integral part of the tripartite synapse. By this way, recent 
discoveries made possible to change perspective regarding the neuro-centric view of chronic 
neurodegenerative disorders, expanding the horizon to new players involved in the physiological 
and/or pathologic processes that take place in CNS. Better understanding the contribution of non-
neuronal cells to these processes will be crucial for the development of new therapeutic approaches 
to counteract neurodegeneration. 
Moving from these assumptions, my studies focused on evaluating the role of glial cells in 
inducing and triggering the inflammatory processes during neurodegeneration and, in particular, 
on the events that lead these cells to an activated state named reactive gliosis. Moreover, the 
consequences caused by these processes on neuronal survival, and in a macroscopic manner, on 
learning and memory, were evaluated. 
To achieve such goals, I worked with different preclinical models of AD, both in vitro and 
in vivo, attempting to recreate at best the pathological hallmarks of pathology. In addition, since 
the crucial role of glial cells in the maintenance of brain homeostasis and their close connection 
with neuronal functioning and survival, the action of different molecules on neuroinflammation, 
as well as on neuronal survival, were tested.  
The first part of the PhD program focused on the role of SIRT1 and SIRT2 modulation in 
an in vitro model of beta amyloid (Aβ) toxicity. Sirtuins (SIRTs) are a family of NAD+-dependent 
enzymes, involved in the control of a variety of biological processes that have the potential to 
modulate neurodegeneration. The possibility to activate SIRT1 or inhibit SIRT2 in order to prevent 
reactive gliosis induced by Aβ(1-42) was tested in primary rat astrocytes. Aβ-activated astrocytes 
were treated with either resveratrol (RSV), a SIRT1 activator, or AGK-2, a SIRT2-selective 
inhibitor. Results shown that RSV and AGK-2 controlled both astrocytes activation and 
inflammation (Section I). 
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During the same period, I was involved in a study aimed at investigating the anti-
inflammatory and neuroprotective properties of palmitoylethanolamide (PEA) in an in vivo model 
of AD. To this purpose, adult rats were injected with Aβ(1-42) in hippocampus and, starting from 
the day of surgery, were intraperitoneally treated with PEA for 7 days. Moreover, to assess PEA 
molecular mechanism, a group of rats was i.p. treated with GW6471, a selective peroxisome 
proliferator-activated receptor-α (PPAR-α) antagonist.  
Results from molecular biology and behavioural experiments confirmed that Aβ(1-42) infusion 
causes reactive gliosis, exacerbating amyloidogenesis, tau hyperphosphorylation, and cognitive 
deficit. PEA treatment had a great anti-inflammatory and neuroprotective action, restoring the 
behavioural outcomes by activating PPAR-α (Section II). 
During the second part of my PhD, I further explored the pharmacological properties of 
PEA by using a triple transgenic mouse model of AD (3xTg-AD). These mice harbour three human 
transgenes strongly correlated with AD (APPswe, PS1M146V and tauP301L), and express both senile 
plaques (SPs) and neurofibrillary tangle (NFTs). 3xTg-AD and Non-Tg mice received vehicle or 
ultra-micronized PEA (um-PEA) for three months through a depot delivery system subcutaneously 
implanted. Hippocampal tissues from mice of two different ages, 6-month-old (corresponding to 
a pre-symptomatic stage) and 12-month-old (corresponding to full-blown disease) were tested.  
Results shown that hippocampi of 3xTg-AD mice, especially those deriving from 6-month-old 
animals, presented a reactive astrocytic state, impairment of the Akt/GSκ-3β pathway involved in 
tau phosphorylation and neuronal survival, and amyloidogenic pathway exacerbation. um-PEA 
chronic treatment was able to restore the deregulated parameters in each pathway studied, at both 
ages. It is noteworthy that um-PEA had a positive effect even in ageing when we tasted it in 12-
month-old Non-Tg mice.  
From these data, we can conclude that um-PEA has a promising effect on neuroinflammation and 
neuronal survival in 3xTg-AD model, especially in precocious stages of the disease, as well as on 
the aging process (Section III). 
Last part of the research activity has been performed in Copenhagen, Denmark, at the 
Center of Basic and Translational Neuroscience of University of Copenhagen (KU). The research 
activity was followed by Prof. Maiken Nedergaard from KU. 
These studies focused on long term potentiation (LTP), widely considered one of the primary 
mechanisms underlying learning and memory, processes strongly impaired in AD. 
In order to further study the cross-talk between glia and neurons and, in particular, the 
physiological mechanisms involved in tripartite synapses, a chemical protocol, design by KU lab, 
able to induce LTP was used.  
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LTP is a form of synaptic plasticity characterized by a persistent strengthening of synapses and 
associated increase in dendritic spines volume taking place after high frequency stimulations. 
Although K+ level in the dendritic cleft has been suggested to be involved in the process of synaptic 
potentiation, the effect of physiological K+ concentration on the macroscopic increase in volume 
of dendritic spines is still poorly investigated. At this early step of the study, we focused on neurons 
in order to expand the study to other players involved in the induction of LTP and K+ regulation, 
astrocytes. 
This preliminary data shown that the area of dendritic spines in the CA1 region of hippocampus is 
increased after LTP induced by briefly superfusing acute mouse brain slices to a higher 
concentration of K+ (20 mM). Notably, K+ concentration where the measured changes occur has 
been demonstrated to peak around 8 mM, suggesting that the phenomenon is physiologically 
relevant (Section IV). 
 
The present dissertation collects most of the results obtained during my PhD. 
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SECTION I 
 
Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer’s disease 
 
INTRODUCTION 
 
Alzheimer’s disease (AD) represents one of the major health concerns and it is a research 
priority since there is a pressing need to develop new agents to prevent or treat it. A part of the 
progressive deposition of beta amyloid peptide (Aβ) and accumulation of phosphorylated tau, 
several other alterations occur in AD brain, all bringing to neuronal loss. Among these, growing 
interest has been attracted by the role of inflammation in the onset and progression of this disorder. 
In fact, senile plaques and neurofibrillary tangles (which are considered the more characteristic 
hallmarks of AD) co-localize with activated astrocytes, suggesting for these cells a key role in the 
pathogenesis of AD (Meda et al., 2001; Craft et al., 2006). Along this line, in several experimental 
models it has been demonstrated that Aβ peptide fragments markedly alter astrocytes functions. 
This process is accompanied with a noticeable neuroinflammatory response, accounting for the 
synthesis of different cytokines and pro-inflammatory mediators which amplify neuropathological 
damage (Mrak and Griffin, 2001a; Caricasole et al., 2003; Tuppo and Arias, 2005; Griffin, 2006; 
Scuderi et al., 2011, 2012, 2013). It is established that neuroinflammation is directly linked to 
neural dysfunction and cell death, representing a primary cause of neurodegeneration (Block and 
Hong, 2005). In fact, over-release of pro-inflammatory cytokines by glia cells causes neuronal 
dysfunction and synaptic loss, which correlate with memory decline. These phenomena are 
believed to precede neuronal death. Thus, research focused on developing therapeutic strategies 
directed at controlling the prolonged and uncontrolled glia activation should be encouraged. 
An uncommon opportunity to improve inflammation and neurodegeneration 
simultaneously is provided by compounds able to modulate histone acetylation/deacetylation, 
since they participate in brain immune control and neuroprotection, in addition to their well-known 
effects on the molecular mechanisms associated to senescence and metabolic syndromes. 
Mounting evidence indicates that sirtuins (SIRTs) exert neuroprotective effects in several models 
of neurodegeneration (Outeiro et al., 2008; Tang and Chua, 2008; de Oliveira et al., 2010). SIRTs, 
a family of NAD+-dependent enzymes with seven isoforms identified (SIRT1-7), are implicated 
in the control of a variety of biological processes including transcriptional silencing, chromosomal 
stability, cell cycle progression, apoptosis, autophagy, metabolism, growth suppression, 
inflammation, and stress response (Gan and Mucke, 2008; Haigis and Sinclair, 2010). 
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Recent observations indicate that both SIRT1 and SIRT2 regulate neuronal survival, but 
with divergent functional outcomes. Indeed, activation of SIRT1 mainly exerts neuroprotective 
actions, while SIRT2 fosters neurodegeneration. The reason for such opposite effect may be due 
to their different sub-cellular localization, which gives SIRT1 and SIRT2 distinct molecular targets 
(Harting and Knöll, 2010). It has been demonstrated that the overexpression of SIRT1 prevents 
neuronal death in tissue culture models of AD, amyotrophic lateral sclerosis, and polyglutamine 
toxicity, and it reduces hippocampal degeneration in a mouse model of AD (Kim et al., 2007; Li 
et al., 2007b). Moreover, treatment with resveratrol (RSV), a polyphenolic compound acting as a 
pharmacological activator of SIRT1, is protective in several experimental neurodegeneration 
paradigms (Anekonda, 2006; Sun et al., 2010). RSV, like other polyphenol compounds including 
curcumin, displays a plethora of actions, behaving as a potent antioxidant agent, increasing 
SUMOylation, and activating protein kinase C, all mechanisms able to counteract astrocyte 
reactivity and protect neurons (Jefremov et al., 2007; Hoppe et al., 2013; Menard et al., 2013). 
Finally, it has been observed that both SIRT1 overexpression and RSV treatment are able to 
significantly decrease the Aβ-induced activation of NF-κB, thus operating a simultaneous control 
on both neurodegeneration and neuroinflammation processes (Chen et al., 2005). Indeed, NF-κB 
is a transcription factor which controls the expression of gene products involved in key cellular 
signaling, including those associated to inflammatory and degenerative events. Post-mortem 
studies on cerebral cortices from AD patients have established a correlation between loss of SIRT1 
and the accumulation of Aβ and hyperphosphorylated tau proteins (Julien et al., 2009). Growing 
evidence indicates that also SIRT2 is involved in regulating several brain processes including 
oligodendrocyte mitosis and differentiation, cytoskeletal dynamics necessary for trafficking, 
neurite outgrowth and synaptic remodelling. Unlike SIRT1, SIRT2 appears to promote neuronal 
death. In fact, blocking SIRT2 counteracted alpha synuclein toxicity in Parkinson’s disease models 
(Outeiro et al., 2007). However, less is known about the role of SIRT2 in AD. 
On the basis of these considerations, we explored the effects of modulators of SIRTs on 
astrocyte activation and the subsequent inflammatory process. In particular, our experiments 
focalized the ability of RSV, a SIRT1 activator, and AGK-2, a SIRT2-selective inhibitor, to control 
astrocyte activation and to suppress the production of pro-inflammatory mediators in primary rat 
astrocytes exposed to Aβ peptide. These findings suggest that either RSV or AGK-2 may be an 
effective agent for neurodegenerative diseases initiated or maintained by inflammatory processes. 
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MATERIALS AND METHODS 
 
Cell cultures and treatments 
Newborn Sprague-Dawley rats (1 or 2 days old) were used to obtain primary astroglial 
cultures (Vairano et al., 2002; Scuderi et al., 2011). Briefly, brain cortices were homogenized and 
processed to obtain single cells. Astrocytes were cultured at a density of 3 × 106 cells/75-cm2 flask 
and incubated at 37°C in a humidified atmosphere containing 5% CO2. The culture medium used 
was Dulbecco's modified eagle medium (DMEM) supplemented with 5% inactivated fetal bovine 
serum, 100 IU/ml penicillin and 100 μg/ml streptomycin (all from Sigma-Aldrich, Milan, Italy), 
replaced 24 h after isolation and again one a week until astrocytes were grown to form a monolayer. 
Approximately 14-15 days after dissection, astrocytes were mechanically separated from 
microglia and oligodendrocytes. Obtained astrocytes were seeded onto 10-cm-diameter Petri 
dishes (1 × 106 cells/dish) or onto 24 well plates (1 × 105 cells/well). The monoclonal anti-glial 
fibrillary acidic protein (GFAP) was used to verify cell culture purity. Only cultures with more 
than 95% GFAP-positive cells were utilized. The 5% of non-astrocyte cells were microglia and 
oligodendrocytes. 
All experiments were performed in accordance with the Italian Ministry of Health (DL 
116/92), the Declaration of Helsinki, and the Guide for the Care and Use of Mammals in 
Neuroscience and Behavioral Research, and they were approved by the Institutional Animal Care 
and Use Committee at our institution. 
Mature astrocytes were challenged with 0.23 μM Aβ(1-42) (Tocris Bioscience, Bristol, UK) 
in the presence or absence of the following substances: RSV (2 - 10 - 50 μM), a well-known SIRT1 
activator, or AGK-2 (0.35 - 3.5 - 35 μM), a potent SIRT2-selective inhibitor (both from Sigma-
Aldrich). After 24 (for viability and protein expression analyses) or 72 h (for proliferation assay) 
of treatment, astrocytes were collected for experiments. The concentration of the substances was 
chosen according to literature (Howitz et al., 2003; Outeiro et al., 2007; Scuderi et al., 2011, 2012). 
 
Analysis of astrocyte viability by neutral red uptake assay  
Astrocyte viability was evaluated 24 h after treatments by the neutral red uptake assay 
according to Repetto et al. (2008), with some modifications (Scuderi and Steardo, 2013). Cells 
were seeded in 24-well plates and treated as previously described. 24 h after treatments, the plates 
were incubated for 3 h at 37°C with a neutral red working solution (50 μg/ml in PBS without 
calcium and magnesium, Sigma-Aldrich). The cells were washed and the dye removed from each 
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well through a destain solution (ethanol : deionized water : glacial acetic acid, 50:49:1, v/v). The 
absorbance was read at 540 nm using a microplate spectrophotometer (Epoch, Bio Teck, 
Winooski, VT, USA). The values of treated cells were referred to control non-exposed cultures, 
and expressed as percentage variation. 
 
Analysis of astrocyte proliferation by trypan blue assay  
Trypan blue exclusion assay was performed to monitor astrocyte proliferation 72 h after 
treatments. This method is based on the principle that living cells do not take up the dye, whereas 
dead cells do. To determine the number of cells and their viability using trypan blue, 20 μl of 
trypsinized and re-suspended cells were mixed with 20 μl of 0.4% solution of trypan blue dye 
(Sigma-Aldrich) for 1 min. Cells were immediately counted using a Bürker chamber with a light 
microscope. All counts were done using four technical duplicates of each sample. 
 
Analysis of protein expression by western blotting  
Western blot analyzes were performed on extracts of cell cultures challenged as previously 
described. 24 h after treatment, cells were detached from Petri dishes and each pellet was 
suspended in ice-cold hypotonic lysis buffer containing NaCl 150 mM; tris/HCl pH 7.5 50 mM; 
triton X-100 1%; ethylenediaminetetraacetic acid (EDTA) 1 mM, supplemented with PMSF 1 
mM, aprotinin 10 μg/ml, leupeptin 0.1 mM (Roche, Mannheim, Germany). After incubation for 
40 min at +4°C, homogenates were centrifuged at 14000 rpm for 15 min and the supernatant 
removed and stored in aliquots at -80°C until use. Equivalent amounts (70 μg) of each sample 
calculated by Bradford assay were resolved on 12% acrylamide SDS-PAGE precast gels (Bio-Rad 
Laboratories). Proteins were transferred onto nitro-cellulose. Membranes were blocked with 5% 
wt/v no-fat dry milk powder in tris-buffered saline-tween 0.1% (TBS-T) for 1 h before overnight 
incubation at +4°C with one of the following primary antibodies: rabbit anti-GFAP (1:50000, 
Abcam plc, Cambridge, UK), rabbit anti-S100β (1:1000, Epitomics, Burlingame, CA, USA), 
rabbit anti-inducible nitric oxide synthase (iNOS; 1:9000, Sigma-Aldrich), rabbit anti-
cyclooxygenase-2 (COX-2; 1:1000, Cell Signaling Technology, MA, USA), rabbit anti-β-actin 
(1:1500, Santa Cruz Biotechnology, Santa Cruz, CA, USA). After being extensively washed in 
TBS-T, membranes were incubated for 1 h at +25 °C with the secondary horseradish peroxidase-
conjugated antibody (HRP conjugated goat anti-rabbit IgG, 1:30000, Jackson Immunoresearch 
Europe, Suffolk, UK). The immunocomplexes were visualized using an ECL kit (Amersham, 
Bucks, UK). Protein expression was quantified by densitometric scanning of the X-ray films with 
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a GS 700 Imaging Densitometer (Bio-Rad laboratories) and a computer program (ImageJ software 
v1.44p, NIH, USA). 
 
Statistical analysis 
Analysis was performed using GraphPad Prism (GraphPad Software, San Diego, CA, 
USA). Data were analyzed by one way analysis of variance (ANOVA) to determine statistical 
differences between experimental groups. Multiple comparisons were performed with 
Bonferroni’s test for post hoc analyzes. Differences between mean values were considered 
statistically significant when p < 0.05. 
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RESULTS 
 
Effect of RSV and AGK-2 on astrocyte viability and proliferation 
First of all, we decided to perform experiments to assess the effect of the SIRTs modulators on 
astrocyte viability and proliferation after Aβ(1-42) challenge. In fact, it has been already 
demonstrated that Aβ peptides are able to affect cell viability and to induce astrocyte proliferation 
(Allaman et al., 2010; Scuderi et al., 2012). Our results highlighted a significant increase in cell 
viability after 24 h treatment with Aβ(1-42) (p < 0.01; Figure 1A, C). RSV and AGK-2 were able to 
reduce this effect at the two higher concentrations used (Figure 1A, C). In addition, we found a 
reduction in cell viability after treatment with AGK-2 at the concentration of 35 μM on 
unstimulated cells, indicating a cytotoxic effect (Figure 1C). Trypan blue experiments revealed a 
significant astrocyte proliferation after 72 h treatment with Aβ(1-42) (p < 0.01; Figure 1B, D). Once 
again, both RSV and AGK-2 significantly controlled such increase at the two higher 
concentrations used. Surprisingly, RSV 50 μM and AGK-2 35 μM caused a reduction in 
proliferation rate also in unchallenged astrocytes (Figure 1B, D). 
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Figure 1 Resveratrol (RSV) and AGK-2 affect astrocyte viability and proliferation induced 
by Aβ(1-42) challenge 
(A, C) Cells were challenged with 0.23 μM Aβ(1-42) in the presence or absence of one of the 
following substances: RSV (2 - 10 - 50 μM), a potent SIRT1 activator; AGK-2 (0.35 - 3.5 - 35 
μM), a selective SIRT2 inhibitor. 24 h later cell viability was assessed by neutral red uptake assay. 
(B, D) 74 h after treatments cell proliferation was evaluated by trypan blue assay. Results are 
expressed as cell viability-fold increase versus unchallenged (open bars) or Aβ-challenged cells 
(black bars). Results are the mean ± SEM of four experiments in triplicate. Statistical analysis was 
performed by one-way ANOVA followed by Bonferroni multiple comparison test. °° p < 0.01 Aβ-
challenged versus unchallenged cells; * p < 0.05; ** p < 0.01; *** p < 0.001 for multiple 
comparison among groups.  
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Effect of RSV and AGK.2 on astrocyte activation  
In order to test the effect of RSV and AGK-2 on Aβ-induced astrogliosis, the expression 
of GFAP and S100β, specific markers of astrocyte activity, was explored. Reactive astrocytes 
display hypertrophied cell bodies and thickened processes exhibiting GFAP-immunoreactivity 
(O’Callaghan and Sriram, 2005; Olabarria et al., 2010). Using western blot analysis, we observed 
a marked increase in the expression of GFAP after Aβ(1-42) challenge (p < 0.01; Figure 2). RSV 
was able to significantly attenuate such increase in a concentration-dependent manner (Figure 2A, 
B). Likewise, the Aβ-induced GFAP overexpression was counteracted by AGK-2 at the three 
concentrations used (Figure 2C, D). 
Similarly, the expression of S100β was investigated by western blot. S100β is an astroglia-
derived protein which acts as a neurotrophic factor and neuronal survival protein, even though the 
overproduction of S100β by activated astrocytes leads to further neurodegeneration. Elevated 
S100β levels are generally associated with a sustained reactive gliosis (Griffin, 2006; Donato and 
Heizmann, 2010). Results from cultured astrocytes showed a significant increase in S100β protein 
expression after Aβ(1-42) exposure (p < 0.01; Figure 2). Both RSV and AGK-2 controlled such an 
increase. Also in this case, RSV exerted its effect in a concentration-dependent manner (Figure 
2A, B). Instead, all the AGK-2 concentrations completely abolished the Aβ-induced S100β 
increase (Figure 2C, D).  
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Figure 2 Effect of RSV and AGK-2 on GFAP and S100 β expression. 24 h after treatments, 
astrocytes were lysated and protein expression was evaluated 
(A, B) Representative western blots for GFAP and S100β proteins in lysates from astrocytes 
challenged with Aβ(1-42) (0.23 μM) in the presence of (C) RSV (2 - 10 - 50 μM) or (D) AGK-2 
(0.35 - 3.5 - 35 μM). Densitometric analyses normalized to β-actin loading controls. Results are 
the mean ± SEM of four experiments in triplicate. Statistical analysis was performed by one-way 
ANOVA followed by Bonferroni multiple comparison test. °° p < 0.01 Aβ-challenged versus 
unchallenged cells; * p < 0.05; ** p < 0.01; for multiple comparisons among groups. 
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Effect of RSV and AGK-2 on inflammation  
Another set of experiments aimed at assessing the effect of RSV and AGK-2 on the 
production of inflammatory factors induced by Aβ(1-42) challenge. In fact, astrocyte activation is 
linked to the production of pro-inflammatory mediators which, in turn, stimulates gliosis and can 
kill neighbouring neurons (Mrak and Griffin, 2001a; Ferreira et al., 2014). Treatment with Aβ(1-
42) resulted in an increase in iNOS expression, as determined by western blot analysis (p < 0.05; 
Figure 3). Interestingly, this observed effect was reduced by both RSV and AGK-2 at the two 
higher concentrations used (Figure 3). Parallel results were obtained with immunoblot experiments 
aimed at studying COX-2 expression. In fact, Aβ(1-42) significantly increased COX-2 protein 
expression (p < 0.05; Figure 3). Also in this case, both RSV and AGK-2 significantly decreased 
such effect at the two higher concentrations used (Figure 3). 
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Figure 3 Effect of RSV and AGK-2 on iNOS and COX-2 expression 
Astrocytes were treated with Aβ(1-42) (0.23 μM) in the presence of RSV (2 - 10 - 50 μM) or AGK-
2 (0.35 - 3.5 - 35 μM). Western blot experiments were carried out 24 h after treatments. (A, B) 
Representative immunoblots for iNOS and COX-2 proteins. (C, D) Densitometric analyses 
normalized to β-actin loading controls. Results are the mean ± SEM of four experiments in 
triplicate. Statistical analysis was performed by one-way ANOVA followed by Bonferroni 
multiple comparison test. ° p < 0.05 and °°° p < 0.001 Aβ-challenged versus unchallenged cells; * 
p < 0.05; ** p < 0.01; for multiple comparison among groups.  
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DISCUSSION 
 
The purpose of this study was to assess the efficacy of RSV, a well-known SIRT1 activator, 
and AGK-2, a potent SIRT2-selective inhibitor, in counteracting reactive gliosis, now considered 
one of the characteristic phenomena occurring in AD. AD leads to disability and death in a 
significant proportion of the world’s aged population (Alzheimer’s Association Report, 2013). 
However, the available treatments are limited and exert only symptomatic effects. Several 
promising drugs have recently failed to provide benefit, so there is an urgent need to develop new, 
and hopefully more efficacious drugs to affect AD course. To this attempt, in the last years 
researchers focused their attention on the role of reactive gliosis in the onset and progression of 
many neurodegenerative disorders, including AD. Produced results gave evidence that 
neuroinflammation and neurodegeneration mutually have a critical impact on AD course (Wyss-
Coray and Rogers, 2012). For this reason, it is possible to assume that early combination of 
neuroprotective and anti-inflammatory treatments represents a particularly appropriate approach 
to AD (Di Filippo et al., 2008). Although neurodegenerative disorders have distinct clinical 
manifestations, many of the underlying pathogenic processes are similar (intra- or extracellular 
accumulation of misfolded proteins, cytoskeletal abnormalities, disruption of calcium 
homeostasis, mitochondrial dysfunction, and inflammation), and most of them are strongly 
influenced by and increased during aging. In particular, in both early- and late-onset sporadic AD, 
aging represents a major contributing factor for the disease development and progression, although 
the precise role remains still unclear. Transcriptional profiling studies revealed that expression of 
genes that play central roles in synaptic plasticity, vesicular transport and mitochondria function 
is reduced, whereas expression of genes encoding for stress, inflammatory or immune factors is 
increased in aged human frontal cortex (Lu et al., 2004). These findings implicate ongoing DNA 
damage, oxidative stress, and inflammation as contributors to the functional decline occurring in 
age-related neurodegenerative diseases, including AD. 
In this context, the discovery of SIRTs, indicated as class III histone deacetylases 
(HDACs), offers a close relationship between aging, metabolism and neurodegeneration, thereby 
representing an innovative target to develop therapeutic strategies (Outeiro et al., 2008). SIRTs 
play pleiotropic biological functions that range from repression of gene expression (through 
histone deacetylation) to regulation of cellular differentiation and/or apoptotic processes, from 
control of energetic cell metabolism to that of aging events. These enzymes have been extensively 
studied because of their involvement in mediating the effect of caloric restriction (CR) in fostering 
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longevity and healthy aging. In addition, many data indicate that SIRTs are potentially able to 
delay neurodegenerative diseases related to senescence, including AD. (Michan and Sinclair, 
2007). It has been demonstrated that CR reduces the content of Aβ in the temporal cortex of 
squirrel monkeys, and such effect is inversely linked to SIRT1 expression in the same brain region 
(Qin et al., 2006a). Moreover, in a transgenic mouse model of AD, the same authors previously 
demonstrated that CR antagonizes Aβ neuropathology by increasing the SIRT1 and 
NAD+/nicotinamide ratio (Qin et al., 2006b). Recently, SIRT2 inhibition has been proposed as a 
promising therapeutic strategy to achieve neuroprotection in in vitro and in vivo models of 
Parkinson’s and Huntington’s diseases (Outeiro et al., 2007; Luthi-Carter et al., 2010). Moreover, 
Spires-Jones et al. (2012) demonstrated that inhibition of SIRT2 is a safe and promising 
neuroprotective agent in both tau-associated frontotemporal dementia and AD. 
It is recognized that Aβ affects cell viability and proliferation (Allaman et al., 2010; Scuderi 
et al., 2012). It is possible to speculate that these Aβ actions are due to its ability to enhance 
astrocyte metabolism turning on morpho-functional changes in such cells (Verkhratsky and Butt, 
2007). Interestingly, our experiments highlighted alterations in astrocyte viability and proliferation 
after Aβ(1-42) challenge, and both RSV and AGK-2 markedly controlled these effects. SIRTs are 
considered as sensors of cell metabolic state because they finely modulate physiological processes. 
For this reason, it is important to establish the appropriate concentrations to avoid dangerous 
unwanted consequences. In fact, in our conditions, we found that the highest concentrations used 
of both RSV and AGK-2 caused cytotoxic effects. 
As a consequence of exogenous insults, glial cells lost their physiological functions and 
acquire a reactive phenotype, characterized by profound morphological and functional alterations, 
such GFAP and S100β overexpression (O’Callaghan and Sriram, 2005; Donato et al., 2013). In 
our model, we detected marked alteration of both these proteins. In fact, western blot analysis 
showed that astrocytes express higher GFAP and S100β protein levels after Aβ challenge. 
Interestingly, RSV and AGK-2 negatively modulated the expression of both GFAP and S100β. 
As mentioned before, the direct correlation between the Aβ-induced toxicity and the 
production of pro-inflammatory mediators prompted us to investigate the expression of the two 
main inducible enzymes related to inflammation, iNOS and COX-2. In our experimental condition, 
we highlighted the existence of an inflammatory state induced by Aβ(1-42) treatment, as detected 
by the increased expression of both iNOS and COX-2. The alteration of these two proteins was 
significantly blunted by RSV and AGK-2, indicating a key role in regulating astrogliosis and 
important astrocyte changes, which contribute to disease progression. In the current study, it was 
observed that SIRT1 and SIRT2 can represent promising targets, whose manipulation could 
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prevent over-activation of neuroglia upon pro-inflammatory stimulation. These data suggest a 
SIRT-dependent mechanism to restrain detrimental effects of excessive astrocyte activation. 
Moreover, the findings bear major implications in the context of several inflammatory conditions 
of the CNS where astroglia is known to mediate deleterious consequences. In conclusion, the 
results of the present study provide evidence that SIRTs modulation can represent a strategy to 
counteract reactive gliosis, and suggest new avenues to walk for the discovery of novel and 
promising therapy for AD. 
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SECTION II  
 
Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat 
model of Alzheimer's disease 
 
INTRODUCTION 
 
Alzheimer's disease (AD) is the most common late-onset and progressive 
neurodegenerative disorder (Querfurth and LaFerla, 2010). It is characterized by progressive 
dementia including episodic memory impairments and involvement of other cognitive domains 
and skills (Dubois et al., 2010). Although senile plaques (SPs) and neurofibrillary tangles (NFTs) 
are considered pathognomic (Blennow et al., 2006), the concept that these are the only significant 
pathological changes occurring in AD brain is misleading. In fact, both in vitro and in vivo findings 
have demonstrated that beta amyloid (Aβ) fragments promote a marked neuroinflammatory 
response, accounting for the synthesis of different cytokines and pro-inflammatory mediators 
(Mrak and Griffin, 2001b). A chronic inflammation goes beyond physiological control and 
eventually detrimental effects override the beneficial effects. In fact, after their release, pro-
inflammatory signaling molecules may act autocrinally to self-perpetuate reactive gliosis and 
paracrinally to kill neighbouring neurons, thus amplifying the neuropathological damage. Once 
started, the inappropriate and prolonged inflammatory process may contribute independently to 
neural dysfunction, cell death, and disease progression (Wyss-Coray, 2006; Block and Hong, 
2005). Besides the sustained production of pathogenic substances, astrocytes fail to provide their 
neuro-supportive functions, making neurons more vulnerable to toxic molecules (Verkhratsky et 
al., 2013). Therefore, targeting neuroinflammation might be an effective therapeutic strategy in 
AD (Fuller et al., 2010; Esposito et al., 2011; Cowley et al., 2012; Medeiros and LaFerla, 2013). 
At present, no therapies in clinical use are able to effectively impact the disease course. 
Therefore, new drugs able to simultaneously ameliorate the numerous pathogenic mechanism 
involved in AD are therapeutically promising. 
Palmitoylethanolamide (PEA) has attracted much attention for its proven anti-
inflammatory and neuroprotective properties reported in many neuropathological conditions other 
than AD. PEA, a naturally occurring amide of ethanolamine and palmitic acid, is a lipid messenger 
that mimics several endocannabinoid-driven actions, even though it does not bind cannabinoid 
receptors (Skaper et al., 1996; Cadas et al., 1997; Calignano et al., 1998; Franklin et al., 2003; Lo 
Verme et al., 2005; Mackie and Stella, 2006; Murillo-Rodriguez et al., 2006; Gatti et al., 2012; 
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Keppel Hesselink et al., 2013). PEA is abundant in the central nervous system (CNS) and it is 
conspicuously produced by glial cells (Cadas et al., 1997; Murillo-Rodriguez et al., 2006). Many 
of its beneficial properties have been considered to be dependent on the activation of the 
peroxisome proliferator-activated receptor-α (PPAR-α) (Lo Verme et al., 2005; Lo Verme et al., 
2006). Recent reports from our group showed the ability of PEA to attenuate in vitro the Aβ-
induced upregulation of a wide range of inflammatory mediators by interacting at the PPAR-α 
nuclear site (Scuderi et al., 2012; Scuderi and Steardo, 2013). Both PPAR-α and PEA are clearly 
detected in the CNS and their expression may largely change during pathological conditions 
(Petrosino et al., 2010). It has been observed that Aβ significantly blunts PPAR-α in primary rat 
astrocytes, suggesting the possibility that the downregulation of this receptor may represent one 
of the molecular mechanisms by which Aβ induces astrocyte activation and possibly exerts 
toxicity. In addition, PEA is able to reverse the downregulation of PPAR-α induced by Aβ, thus 
mitigating the overexpression of pro-inflammatory molecules and signals (Scuderi et al., 2011). 
Therefore, we explored the anti-inflammatory and neuroprotective effects of PEA in an in 
vivo model of AD. The present study also incorporates pharmacological experiments to test the 
hypothesis that PPAR-α was involved in the effects induced by PEA administration. To this 
purpose, we co-administered PEA with the GW6471 (N-((2S)-2-(((1Z)-1-methyl-3-oxo-3-(4-
(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy) 
phenyl)propyl)propanamide), a PPAR-α antagonist. These experiments are much needed because 
PEA is currently clinically used for a condition other than AD. Moreover, its safety and tolerability 
in humans further demonstrate the translational value of this work. 
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MATERIALS AND METHODS 
 
Animals 
Male adult Sprague-Dawley rats (250-275 g at the time of surgery; Charles River 
Laboratories, Calco, Italy) were individually housed in a temperature-controlled (20 ± 1 °C) 
vivarium and maintained under a 12 h light/dark cycle (07 : 00 AM lights on - 07 : 00 PM lights 
off). Food and water were available ad libitum. All experiments were carried out during the light 
phase. All procedures were approved by the Italian Ministry of Health (Rome, Italy) and performed 
in compliance with the guidelines of the European Communities Council (2010/63/UE). 
 
Surgical procedures 
Rats (n = 9-12 for each experimental group) were anesthetized intraperitoneally (i.p.) with 
sodium pentobarbital (50 mg/kg), placed in a stereotaxic frame and unilaterally inoculated with 
human Aβ(1-42) (Tocris Cookson, Bristol, UK) into the dorsal hippocampus (coordinates relative to 
the bregma: AP: -3 mm, ML: ±2.2 mm, and DV: -2.8 mm) (Paxinos et al., 2007). The coordinates 
and dose of Aβ(1-42) were chosen according to literature and the results of a series of pilot 
experiments (Durán-González et al., 2013). The peptide was dissolved in artificial cerebral-spinal 
liquid (aCSF) to the concentration of 2 μg/μl. Fibrillar amyloid was formed by incubation at least 
for 24 h at +37 °C (De Felice et al., 2008). A volume of 2.5 μl was injected using a microdialysis 
pump, keeping the flow to the constant value of 0.5 μl/min. Injection needles were left in place for 
additional 60 s to facilitate the diffusion of solution. Control rats underwent the same procedure 
and were inoculated with an equivalent volume of aCSF.  
 
Drug treatment 
PEA and GW6471 were both from Tocris (Bristol, UK). PEA and GW6471 were dissolved 
in saline : PEG : Tween-80 in a 90 : 5 : 5 ratio (v/v) (Sigma-Aldrich, Milan, Italy). Control rats 
were i.p. given an equivalent volume of the proper vehicle. Vehicle, PEA (10 mg/kg), GW6471 
(2 mg/kg), or both drugs were i.p. administered once a day for seven consecutive days, starting 
from the day of the surgery. The doses were chosen according to literature and the results of a 
series of pilot experiments (Sheerin et al., 2004; Kapoor et al., 2010) (data not shown).  
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Biochemical evaluations 
Tissue collection Twenty-eight days after surgery, rats were killed by decapitation. For 
immunoblotting, ELISA, and RT-PCR experiments, hippocampi were isolated and frozen using 
2-methylbutane. We focused on the hippocampus, which is one of the brain areas earliest and most 
severely affected by AD. For morphological analysis, whole brains were frozen in 2-methylbutane 
and stored at -80 °C. 
 
Reverse transcriptase-polymerase chain reaction 
Total RNA was extracted from homogenized hippocampi ipsilateral to the injection site 
using the lysis reagent provided in NZY total RNA isolation kit (NZYTech, Lda., Lisbon, 
Portugal) according to the manufacturer's protocol. The extracted RNA was subjected to DNase I 
(NZYTech, Lda) treatment at +25 °C for 15 min and eluted in 30 μl of RNase-free water. The total 
RNA concentration was determined by Nanodrop 1000 spectrophotometer (Thermo-scientific, 
Rockford, IL, USA) and purity of sample was determined according to the 260/280 nm ratio. One 
microgram of RNA was reversed transcribed into complementary DNA (cDNA) using oligo(dT) 
and random primers included in the first-strand cDNA synthesis kit (NZYTech, Lda.); then 
RNA/DNA hybrids were digested with RNaseH from E. coli, according to the manufacturer's 
specifications. All PCR experiments were performed using supreme NZYTaq DNA polymerase 
(NZYTech, Lda.) with specific primers for rattus norvegicus GFAP (forward primer 5′-TGG CCA 
CCA GTA ACA TGC AA-3′ reverse primer 5′-CTC GAT GTC CAG GGC TAG CT-3′), S100β 
(forward primer 5′-TCA GGG AGA GAG GGT GAC AA-3′ reverse primer 5′-ACA CTC CCC 
ATC CCC ATC TT-3′), and GAPDH (forward primer 5′-GCG AGA TCC CGC TAA CAT CAA 
ATG G-3′ reverse primer 5′-GCC ATC CAC AGT CTT CTG AGT GGC-3′) sequences, with the 
latter used as a housekeeping gene. 
Each PCR was preceded by incubation for 5 min at +95 °C to activate Taq-polymerase 
enzyme and followed by 7 min at +72 °C to finish the extension of amplified sequences. 
PCR amplification products were separated on 1.5% agarose gel (BioRad Laboratories, 
Milan, Italy) stained with GelRed (Biotium Inc., Hayward, CA, USA), visualized by ultraviolet 
light, acquired by Versadoc (BioRad Laboratories) and analyzed by a densitometry computer 
programme (ImageJ software v1.44p, NIH, Bethesda, MD, USA). 
 
Western blot 
Western blot analyses were performed on rat-isolated hippocampal region ipsilateral to the 
injection site. Each portion was suspended in ice-cold hypotonic lysis buffer (tris/HCl pH 7.5 
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50 mM, NaCl 150 mM, ethylenediaminetetraacetic acid (EDTA) 1 mM, 1% triton X-100) 
supplemented with the proper protease inhibitor cocktail (PMSF 1 mM, aprotinin 10 μg/ml, 
leupeptin 0.1 mM, all from Sigma-Aldrich). After incubation for 40 min at +4 °C, homogenates 
were centrifuged at 14000 rpm for 15 min and the supernatant removed and stored in aliquots at  
-80 °C until use. 
Equivalent amounts (50 μg) of each sample calculated by Bradford assay were resolved on 
12% acrylamide SDS-PAGE precast gels (BioRad Laboratories). Proteins were transferred onto 
nitrocellulose. Membranes were blocked with 5% w/v no-fat dry milk powder in tris-buffered 
saline-tween 0.1% (TBS-T) for 1 h before overnight incubation at +4 °C with one of the following 
primary antibodies: rabbit anti-GFAP (1 : 50000, Abcam plc, Cambridge, UK), rabbit anti-S100β 
(1 : 1000, Epitomics, Burlingame, CA, USA), rabbit anti-iNOS (1 : 9000, Sigma-Aldrich), rabbit 
anti-COX-2 (1 : 1000, Cell Signaling Technology, Inc, Danvers, MA, USA), rabbit anti-β-actin 
(1 : 1500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti- β-catenin (1 : 1000, Cell 
Signaling Technology, Inc), rabbit anti-BACE1 (1 : 1000, Abcam plc), anti-APP (1 : 1000, Cell 
Signaling Technology, Inc), rabbit anti-Dkk-1 (1 : 1000, Santa Cruz Biotechnology), rabbit anti-
phospho-Gsκ-3β (1 : 1000, Cell Signaling Technology, Inc), rabbit anti-phospho-tau 
(p[Ser396]tau, 1 : 500, Novus Biologicals, Littleton, CO, USA), goat anti-tau (1 : 500, Santa Cruz 
Biotechnology, CA, USA). After being extensively washed in TBS-T, membranes were incubated 
for 1 h at +25 °C in the proper secondary horseradish peroxidase-conjugated antibodies (HRP-
conjugated goat anti-rabbit IgG, 1 : 30000, Jackson Immunoresearch Europe, Suffolk, UK; HRP-
conjugated rabbit anti-goat, 1 : 5000, Abcam plc). The immunocomplexes were visualized using 
an ECL kit (Amersham, Bucks, UK). Protein expression was quantified by densitometric scanning 
of the X-ray films with a GS 700 Imaging Densitometer (Bio-Rad laboratories) and a computer 
programme (ImageJ software). 
 
Enzyme-linked immunosorbent assay 
Hippocampal regions ipsilateral to the injection site were homogenized in lysis buffer (tris-
HCl pH 7.5 20 mM, NaCl 137 mM, NP40 1%, glycerol 10%, sodium orthovanadate 0.5 mM) 
containing a mix of protease inhibitors (PMSF 1 mM, aprotinin 10 μg/ml, leupeptin 1 μg/ml, all 
from Sigma-Aldrich), in a 5 : 1 ratio μl lysis buffer/mg tissue by a mechanical homogenization 
potter. The homogenates were centrifuged at 14000 rpm, at +4 °C for 30 min and the supernatant 
was immediately used for the assay. The concentrations of S100β, TNF-α, and IL-1β were 
measured with commercially available ELISA kit (Invitrogen, Milan, Italy) according to the 
procedures recommended by the manufacturer. The intensity of the colored product, recorded at 
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450 nm with an Epoch Microplate Spectrophotometer (BioTek Instruments, Inc., Winooski, VT, 
USA), was directly proportional to the concentration of cytokines in the sample. 
 
Immunofluorescence 
Extracted brains were transversely cut using a cryostat to obtain coronal sections containing 
the hippocampal region. Sections (10-μm thickness) were fixed for 4 min at room temperature with 
4% paraformaldeyde (Merck, Darmstadt, Germany) in 0.12 M phosphate buffer, pH 7.4. After 
quenching auto-fluorescence with 0.05 M ammonium chloride, and saturation of non-specific sites 
with 3% normal donkey serum (BioCell Research Laboratories, Newport Beach, CA, USA), 
sections were incubated overnight at +4 °C with 0.5% albumin bovine serum/0.25% triton-TBS 
solution containing one of the following primary antibodies: rabbit anti-GFAP (1 : 500; Abcam 
plc), rabbit anti-S100β (1 : 1000, BD Transduction Laboratories, San Jose, CA, USA), mouse anti-
MAP2 (1 : 250, Novus Biologicals). After washing, the sections were incubated with donkey Cy3-
labeled anti-rabbit (or anti-mouse) IgG (1 : 400; Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA). Negative controls were performed substituting specific Igs with an equivalent 
amount of non-specific Igs and omitting primary antibodies. After a final wash with PBS, slides 
were mounted with Vectashield mounting medium, containing DAPI for nuclear staining (Vector 
Laboratories, Burlingame, CA, USA). Pictures were taken using a fluorescence microscope 
(Eclipse E600; Nikon Instruments S.p.A., Firenze, Italy). Analysis of signal intensity was 
measured semi-quantitatively in each slice as optical density (OD) and considering the averaged 
OD of non-immunoreactive regions of the brain for background normalization using a specific 
computer program (ImageJ software). Since many variables affect the staining intensity of a tissue 
section, during the acquisition of images, we set the same values of gain and exposure for each 
channel.  
 
Morris water maze test (MWM) 
Task procedures Eighteen days after surgery, rats were handled 1 min per day for three 
consecutive days before training on the MWM task. The maze, located in a room containing 
several visual cues, was a circular tank (1.83 m in diameter and 0.58 m in height) filled with water 
(+23-24 °C) to a depth of 20 cm. During the spatial training and reversal learning, a hidden 
transparent Perspex platform (20-25 cm) was submerged 2.5 cm below the surface of the water in 
the northwest quadrant of the maze. The experiments were performed according to the procedure 
previously described (Koistinaho et al., 2001; Campolongo et al., 2013).  
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Spatial training (acquisition) Days 1-3. Rats were given a daily training session of four 
trials (60 s each one) for three consecutive days. On each trial, the animal was placed in the tank 
facing the wall at one of the four designated start positions and allowed to escape onto the hidden 
platform. If an animal failed to find the platform within 60 s during the first day of the training, it 
was manually guided to the platform. The rat was allowed to remain on the platform for 10 s and 
was then placed into a holding cage for 25 s until the start of the next trial. The time each animal 
spent to reach the platform was recorded as the escape latency. 
 
Probe (memory retention) Day 4. The retention of the spatial training was assessed 24 h 
after the last training session. At the probe test, the platform was removed and rats were returned 
to the water maze for a 60 s trial. The parameter measured was the time spent by rats to reach the 
position where the platform was previously located (escape latency). 
 
Reversal learning Day 5. Rats were given a single training session of five trials (60 s each 
one); the platform was placed into the quadrant on the opposite side where the platform was 
previously located. On each trial, the animal was placed in the tank facing the wall at one of the 
four designated start positions and allowed to escape onto the hidden platform. If an animal failed 
to find the platform within 60 s during the first trial, it was manually guided to the platform. The 
rat was allowed to remain on the platform for 10 s and was then placed into a holding cage for 15 s 
until the start of the next trial. The time each animal spent to reach the platform was recorded as 
the escape latency. 
Behavioral data from the acquisition, probe, and reversal learning were acquired and 
analyzed using an automated video-tracking system (Smart, Panlab, Harvard Apparatus, Cornellà 
(Barcelona, Spain). The escape latency for the spatial training and reversal learning working 
memory, and the amount of time rats spent in the target zone in the probe test were analyzed. 
 
Statistics 
Analysis was performed using GraphPad Prism version 4.0 (GraphPad Software, San 
Diego, CA, USA). Data were analyzed by one or two-way analysis of variance and multiple 
comparisons were performed using the Bonferroni's post hoc test, when applicable. Data are shown 
as mean ± standard error of the mean (SEM) as specified in the figure legends. Differences between 
mean values were considered statistically significant when p < 0.05. 
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RESULTS 
 
PEA counteracts Aβ-induced reactive gliosis 
Gliosis is a common pathological process after brain injury and neurodegenerative 
disorders such as AD (Verkhratsky and Parpura, 2010; Verkhratsky et al., 2012). On the basis of 
these evidences, we decided to investigate the possible modifications induced by the 
intrahippocampal inoculation of Aβ(1-42) and the potential beneficial effect of systemic 
administration of PEA. First, we studied the transcription and expression of the GFAP protein, 
which is considered one of the most important markers of astrocyte activation. Indeed, GFAP plays 
a role in mediating most of the signals involved in morphology and functional alterations observed 
during astrocyte activation (Verkhratsky and Butt, 2007). Immunofluorescence analysis of the 
hippocampal CA3 area ipsilateral to the injection site revealed that the levels of GFAP were 
significantly different between the vehicle-inoculated and Aβ-inoculated rats (Figure 1a, b). In 
fact, we observed an evident increase in the GFAP intensity, and astrocytes show stellate shape 
and multiple branched processes, which are typical of activated astrocytes (Figure 1b). Such effect 
was counteracted by systemic treatment with PEA. Indeed, GFAP immunopositivity was 
decreased in PEA-treated animals, and the shape of astrocytes resembles the one seen in control 
animals (Figure 1c). Further, the co-administration of PEA with GW6471, a selective PPAR-α 
antagonist, completely abolished PEA-induced effect (Figure 1d, f).  
In line with this observation, results from RT-PCR and western blot experiments, 
performed in homogenates of hippocampi ipsilateral to the injection site, revealed that both 
transcription (p < 0.05) and expression (p < 0.05) of GFAP were significantly higher in Aβ-injected 
rats than in vehicle-injected rats (Figure 1g-j). Moreover, PEA significantly reduced the Aβ-
induced GFAP induction in a PPAR-α-dependent manner (Figure 1g-j). 
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Figure 1 PEA effect on Aβ-induced GFAP protein transcription and expression 
(a-e) Representative fluorescent photomicrographs (20X magnification) of GFAP immunostaining 
(red) in the CA3 region of hippocampi ipsilateral to vehicle or Aβ(1-42) injection obtained from rats 
i.p. treated with vehicle, PEA (10 mg/kg), GW6471 (2 mg/kg), or both drugs. Nuclei were stained 
with DAPI (blue). (f) Data obtained by the semiquantitative analysis of the OD of GFAP 
immunostaining. Data are expressed in arbitrary units as means ± SEM (** p < 0.01). (g) Results 
of GFAP RT-PCR amplification and (h) densitometric analysis of corresponding bands. Data were 
generated normalizing to GAPDH (* p < 0.05). (i) Representative western blots for GFAP protein 
from hippocampi ipsilateral to the injection site. (j) Densitometric analyses normalized to β-actin 
loading controls (* p < 0.05). Statistical analysis was performed by one-way (f) or two-way (h, j) 
ANOVA followed by Bonferroni multiple comparison test. Results presented as means ± SEM of 
five experiments.  
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Another mediator crucially involved in the reactive gliosis is the protein S100β. In physiological 
conditions, S100β behaves as a neurotrophin, promoting the growth of neuritis, stimulating 
astrocyte proliferation, and increasing free calcium concentrations in both neurons and astrocytes. 
On the contrary, in case of brain damage, large amounts of S100β are being passively released 
mainly from astrocytes to diffuse into CSF and blood brain, participating in the amplification of 
the inflammatory response by further activating microglia and astrocytes (Donato and Heizmann, 
2010; Steiner et al., 2011). Experiments revealed increased concentrations of S100β mRNA and 
protein, as well as increased densities of S100β-positive astrocytes, in Aβ-injected rats in 
comparison to the vehicle-injected rats (Figure 2). In particular, immunofluorescence analysis of 
the CA3 area of the hippocampi ipsilateral to the injection site revealed higher levels of S100β 
after Aβ(1-42) insult; PEA was able to prevent such increase through its interaction with PPAR-α 
(Figure 2a-f). RT-PCR, western blot, and ELISA experiments were performed to investigate 
S100β mRNA, protein expression, and release in hippocampal homogenates. Results indicated an 
upregulation of both transcription (p < 0.01) and expression (p < 0.01), as well as an increased 
release (p < 0.01) of S100β in Aβ-injected versus vehicle-injected rats. In these conditions, we 
observed that PEA controlled the Aβ-induced elevation of S100β content in a PPAR-α-dependent 
manner. In fact, GW6471, the selective antagonist for this receptor, completely abolished the 
effects of PEA (Figure 2g-k). 
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Figure 2 Effect of PEA on Aβ-induced S100β protein transcription, expression, and release 
(a-e) Representative fluorescent photomicrographs (20X magnification) of S100β immunostaining 
(red) in the CA3 region of hippocampi ipsilateral to vehicle- or Aβ(1-42) injection site obtained from 
rats i.p. treated with vehicle, PEA (10 mg/kg), GW6471 (2 mg/kg), or both drugs. Nuclei were 
stained with DAPI (blue). (f) Data obtained by the semiquantitative analysis of OD of S100β 
immunostaining. Data are expressed in arbitrary units as means ± SEM (*** p < 0.001; ** p < 
0.01). (g) Results of S100β RT-PCR amplification and (h) densitometric analysis of corresponding 
bands. Data were generated normalizing to GAPDH (** p < 0.01; * p < 0.05). (i) Representative 
western blots for S100β protein from hippocampi ipsilateral to the injection site. (j) Densitometric 
analyses normalized to β-actin loading controls (** p < 0.01; * p < 0.05). (k) Measurement of 
S100β release by ELISA in homogenate hippocampi ipsilateral to the Aβ injection site (*** p < 
0.001; ** p < 0.01). Statistical analysis was performed by one-way (f) or two-way (h-k) ANOVA 
followed by Bonferroni multiple comparison test. Results presented as means ± SEM of five 
experiments.  
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As mentioned before, a protracted glial activation is accompanied with the release of 
several pro-inflammatory mediators that can establish a self-sustaining detrimental cycle that leads 
to neuronal death, and thus to cognitive dysfunctions (Sastre et al., 2006). Among these molecules, 
IL-1β has been particularly linked to the pathophysiology of AD, as IL-1β is involved in 
neurodegeneration (Griffin, 2011; Ben Menachem-Zidon et al., 2014). Aβ stimulates IL-1β 
production which leads to a further increase in glial activation and still more expression of IL-1β. 
IL-1β is able to increase neuronal tau expression and tau hyperphosphorylation (Mrak, 2009), to 
upregulate the complex cdk5/p35, which plays a pivotal role in CNS development, and to induce 
inducible nitric oxide synthase (iNOS) with concomitant production of nitric oxide (NO) (Rojo et 
al., 2008). 
AD chronic neuroinflammation also shows the upregulation of TNF-α expression 
(Hallenbeck, 2010; Frankola et al., 2011) mainly involved in the induction of inflammatory tissue 
damage and neuronal death (Rojo et al., 2008). This neuroinflammatory stimulation is further 
characterized by activation of the complement cascade and induction of the prostanoid-generating 
enzyme cyclooxygenase-2 (COX-2) (Koistinaho et al., 2011), elevated in many neuropathological 
conditions (Frank-Cannon et al., 2009). This inducible enzyme causes neurodegeneration in 
several ways, including the generation of free radicals (Minghetti, 2004). 
Our results demonstrated that Aβ(1-42) injection induced the upregulation of iNOS (p < 0.01) 
and COX-2 (p < 0.01) in comparison with vehicle-injected rats. PEA blunted Aβ(1-42) effect (p < 
0.01) and the administration of GW6471 revealed that PPAR-α is partially involved in mediating 
PEA action (p < 0.05) (Figure 3a-c). 
Similar findings were obtained when ELISA experiments were performed to quantify the 
release of IL-1β and TNF-α in homogenates of hippocampi ipsilateral to the injection site. We 
found a marked release of both these pro-inflammatory cytokines, and PEA, once again, was able 
to control their release. The administration of the selective PPAR-α antagonist, GW6471, 
completely abolished PEA effects, indicating the significant involvement of such a receptor 
(Figure 3d, e). These data clearly show that Aβ peptide causes a marked activation of glial cells, 
starting the so-called reactive gliosis process, which is efficaciously counteracted by PEA 
treatment. In addition, these data confirmed a clear involvement of PPAR-α receptor in mediating 
the effect of PEA. 
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Figure 3 Effect of PEA on expression and release of inflammatory mediators induced by Aβ 
injection 
(a) Representative western blots for iNOS and COX-2 proteins from hippocampi ipsilateral to the 
injection site and (b, c) relative densitometric analyses normalized to β-actin loading controls (** 
p < 0.01; * p < 0.05). Measurement of IL-1β (d) and TNF-α (e) release by ELISA in homogenate 
hippocampi ipsilateral to the Aβ injection site (*** p <0.001; ** p <0.01). Statistical analysis was 
performed by two-way ANOVA followed by Bonferroni multiple comparison test. Results 
presented as means ± SEM of five experiments.  
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PEA effects on amyloidogenic pathway 
β-secretase (BACE1) is a type I transmembrane aspartyl protease. It is predominantly 
expressed in neuronal cells, and localizes to acidic compartments in the secretory pathway where 
the production of Aβ occurs. Indeed, Aβ generation is abolished in BACE1 knockout mice (Luo 
et al., 2001), whereas Aβ formation is increased by the overexpression of BACE1 (Cole and Vassa, 
2008). Cleavage of APP by BACE1 is the first step in a process essential for Aβ generation, and 
several studies demonstrated how BACE1 expression is able to control the dynamics of β-secretase 
activity in processing APP to generate Aβ (Li et al., 2006). Moreover, in vitro studies demonstrated 
that the AD-associated Swedish mutant APP is associated with increased BACE1 activity 
developing the phenotypes typical of axonal transport defects because of an enhanced cleavage of 
APP (Rodrigues et al., 2012). Indeed, the regulation of APP transcription might play an important 
role in AD susceptibility. Several studies identified higher levels of APP mRNA in AD brains 
(Theuns and Van Broeckhoven, 2000), and highlighted that increased expression of APP correlates 
with Aβ deposition in brain with severe head injury (Gentleman et al., 1993). Given the importance 
of these proteins in AD pathogenesis and progression, western blot analysis for BACE1 and APP 
was performed. Our results showed a significant BACE1 and APP protein expression increase (p 
< 0.05 and p < 0.01, respectively) in Aβ-injected rat compared with controls (Figure 4a), as 
confirmed by relative densitometric analysis (Figure 4b, c). This expression is statistically 
attenuated by PEA treatment (p < 0.05 and p < 0.01, respectively, for BACE1 and APP 
expression), when compared with the vehicle-treated group. The selective PPAR-α antagonist, 
GW6471, abolished PEA effects. 
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Figure 4 Effect of PEA on amyloidogenic pathway 
(a) Representative western blots for BACE 1 and APP proteins from hippocampi ipsilateral to the 
injection site and (b, c) relative densitometric analyses normalized to β-actin loading controls (** 
p < 0.01; * p < 0.05). Statistical analysis was performed by two-way ANOVA followed by 
Bonferroni multiple comparison test. Results presented as means ± SEM of five experiments. 
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PEA rescues Wnt pathway thus modulating tau protein phosphorylation 
The irregular phosphorylation of the microtubule-associated protein tau is a prominent 
aspect of AD. It is now established that glycogen synthase kinase 3β (Gsκ-3β) is involved in 
normal and pathological tau phosphorylation. Indeed, activation of the canonical Wnt pathway 
leads to two main molecular mechanisms represented by the inhibition of Gsκ-3β and the relative 
accumulation/degradation of β-catenin in the cytoplasm (Caricasole et al., 2003). The latter 
signaling pathway has been found to be dysregulated in the AD brain (Inestrosa et al., 2012). We 
have already demonstrated that S100β is able to induce the expression of Dickopff-1 (Dkk-1), 
causing tau protein hyperphosphorylation (Esposito et al., 2008). In addition, recent data 
demonstrated the increased expression of Dkk-1 in brains of AD patients suggesting that 
dysfunction of the Wnt signaling could contribute to AD pathology (Zenzmaier et al., 2009). 
Utilizing western blot analysis, we evaluated the expression of the main proteins involved 
in the canonical Wnt pathway. Results of immunoblot experiments and their relative densitometric 
analysis are illustrated in Figure 5. Aβ-injected rats showed increased concentrations of Dkk-1 in 
comparison with vehicle-injected rats (p < 0.05). Under these conditions, PEA was able to control 
Dkk-1 expression in a PPAR-α-dependent manner (Figure 5b). This set of experiments also 
revealed a marked alteration in the levels of the Wnt pathway proteins. In fact, we found a 
significant increase in Gsκ-3β expression in Aβ-injected rats in comparison with vehicle-injected 
rats (p < 0.001). Such effect was totally abolished by the pharmacological treatment with PEA (p 
< 0.001) through a mechanism which partially involves PPAR-α (Figure 5c). In parallel, we 
observed a marked decrease of β-catenin protein in the hippocampus of Aβ-injected rats in 
comparison with vehicle-injected rats (p < 0.01). Physiological levels of β-catenin were founded 
in Aβ-injected rats systemically treated with PEA (p < 0.05) demonstrating, once again, the ability 
of this compound to counteract the damage induced by peptide inoculation. Co-administration of 
PEA with GW6471 attenuated such effect, demonstrating that PEA interacts with PPAR-α to 
achieve the observed effects (Figure 5d). Growing evidence indicates that disrupted Wnt signaling 
may be a direct link between Aβ toxicity and tau hyperphosphorylation, ultimately leading to 
neuronal degeneration. For this reason, we performed western blot experiments using a specific 
primary antibody able to bind tau protein on the phospho-Ser396, which is recognized to be the 
phosphorylation site mainly related to neurofibrillary pathology in AD brain (Cavallini et al., 
2013). The expression of phosphorylated tau (p-[Ser396]) was normalized for total tau content 
using a polyclonal primary antibody. Results highlighted a significant increase in the p-tau/tau 
ratio after Aβ(1–42) injection (p < 0.01), normalized by PEA (p < 0.05) in a manner partially 
dependent on its PPAR-α interaction (Figure 5e). Collectively, these data support a pivotal role of 
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PEA in modulating the Aβ-induced alterations in the Wnt pathway and normalizing the 
physiological level of phosphorylated tau protein.  
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Figure 5 Effects of PEA on the Wnt pathway and tau protein phosphorylation 
(a) Representative western blots from hippocampal proteins probed with the indicated antibodies. 
(b-e) Relative densitometric analyses. Data were generated normalizing proteins of interest to β-
actin loading controls (*** p < 0.001; ** p < 0.01; * p < 0.05). Statistical analysis was performed 
by two-way ANOVA followed by Bonferroni multiple comparison test. Results presented as 
means ± SEM of five experiments.  
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PEA effects on neuronal integrity 
To investigate the effects of Aβ(1-42) injection on neuronal survival, we measured the 
expression of the microtubule-associated protein 2 (MAP2) by immunofluorescence analysis. 
MAP2 is one of the main cytoskeletal proteins in neurons; in mammalian nervous system, MAP2 
regulates microtubule dynamics, and it plays an important role in neurite outgrowth and dendrite 
development (Hirokawa, 1994). Morphologically, the reduction in neurite outgrowth is observed 
in neural cells from AD patients. Indeed, recent studies demonstrated that MAP2 expression 
pattern was significantly reduced compared with the control group, highlighting that mature 
neurons are significantly decreased in the patients' group (Dehghani et al., 2013). In our study, 
results from MAP2-stained hippocampi indicated that Aβ(1-42) injection caused a severe depletion 
of neurons, especially in the dentate gyrus, compared with vehicle-injected rats (p < 0.05). By 
means of MAP2 staining and relative quantification of immunopositive cells, we observed that 
PEA treatment significantly reduced Aβ-provoked neuronal loss (p < 0.05) through its interaction 
with PPAR-α (p < 0.05) (Figure 6a-f). Moreover, our results indicate that PEA was able to exert 
an important neuroprotective effect through PPAR-α involvement. 
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Figure 6 PEA effect on neuronal integrity 
(a-e) Representative fluorescent photomicrographs (20X magnification) of MAP2 
immunostaining (red) in the CA3 region of hippocampi ipsilateral to vehicle or Aβ(1-42) injection 
site obtained from rats i.p. treated with vehicle, PEA (10 mg/kg), GW6471 (2 mg/kg), or both 
drugs. Nuclei were stained with DAPI (blue). (f) Data obtained by the semiquantitative analysis 
of the optical density (OD) of MAP2 immunostaining. Data are expressed in arbitrary units as 
means ± SEM of five experiments (* p < 0.01). Statistical analysis was performed by one-way 
ANOVA followed by Bonferroni multiple comparison test. 
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PEA rescues the Aβ-induced deficits in the reversal learning phase of the Morris water maze 
To examine whether systemic treatment with PEA can result in recovery from memory 
deficit induced by hippocampal Aβ(1-42) infusion, the MWM task was carried out 3 weeks after 
surgery, as illustrated in the flow chart (Figure 7a). Rat weight was monitored every day until the 
beginning of behavioral tests. No alterations were observed (data not shown). 
All groups were trained for three consecutive days on spatial training procedure of four 
trials session per day. During these sessions, rats had to learn to localize a hidden platform set 
always in a fixed place. All rats, regardless of any treatment, were equally able to acquire the 
cognitive task. Indeed, ANOVA for repeated measures (with trials as repeated measures) revealed 
a trial effect (F(11,418) = 35.031; p < 0.0001) but did not reveal significant differences among groups 
in the acquisition performances (F(11,418) = 1.026; p = 0.422) (Figure 7b). 
The effect of Aβ(1-42) inoculation on long-term memory was analyzed 24 h after the last 
acquisition day on a single 60 s probe trial. During the probe test, the platform was removed from 
the water maze tank and the time spent in the target quadrant where the platform was previously 
located was measured as a parameter of long-term memory retention. ANOVA test revealed 
significant differences neither for the central treatment (F(1,38) = 0.506; p = 0.481) nor for the 
peripheral treatment (F(1,38) = 0.464; p = 0.499) nor for the interaction between central and 
peripheral treatments (F(1,38) = 0.623; p = 0.435) showing that Aβ(1-42) did not alter long-term 
memory functions (Figure 7c). 
On day 5, rats were tested for reversal learning capabilities during a unique session of five 
trials. The hidden platform was relocated into the quadrant on the opposite side where the platform 
was previously positioned, thus rats had to quickly understand the new experimental setting, and 
consequently to remodel their escape strategy. Figure 7d shows the effect of PEA administration 
on reversal learning performances during the first trial. ANOVA revealed a statistically significant 
interaction among treatments (F(1,38) = 10.278; p = 0.003). Post hoc comparisons revealed a 
statistically significant difference between Aβ/vehicle (Veh) versus Veh/Veh, and Aβ/Veh versus 
Aβ/PEA animals (p < 0.05), thus showing that Aβ-injected rats were impaired in the fast 
adjustment to a change in the platform location compared with the vehicle-injected animals. 
Interestingly, we found that PEA administration statistically prevented the memory-impairing 
effect induced by Aβ (p < 0.05) (Figure 7d). No statistically significant differences were found 
among groups in the escape latency during trials 2-5 (F(3,114) = 1.36; p = 0.26).  
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Figure 7 PEA rescues the Aβ-induced deficits in the reversal learning phase of the MWM 
(a) Diagram of the experimental design. (b) Mean latency (seconds) for finding the escape 
platform during the spatial training. No significant differences were detected among all groups. 
(c) Mean latency (seconds) to reach the quadrant where the platform was located during the 
acquisition. No significant differences were detected among all groups. (d) Mean latency (seconds) 
for finding the escape platform during the reversal learning. Aβ/Veh rats showed longer escape 
latency versus Veh/Veh (* p < 0.05) and Aβ/PEA rats (* p < 0.05). Statistical analysis was 
performed by two-way ANOVA followed by Bonferroni multiple comparison test. Results are 
presented as means ± SEM.  
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DISCUSSION 
 
The current results clearly demonstrate, for the first time in a rat model of AD, the ability 
of PEA to attenuate neuropathology by modulating neuroinflammation. This supports the view 
that astrocyte-unregulated activation can be considered an appropriate and promising therapeutic 
target for AD treatment. Furthermore, we demonstrated in vivo that PPAR-α is involved in 
mediating PEA beneficial effects. Such findings are new and of great interest because AD 
represents one of the major health concern, with a pressing need to develop new agents able to 
prevent or treat this disorder. Currently, an unresolved goal of preclinical investigation is to 
recognize tools capable to selectively regulate pro-inflammatory overactivation of neuroglia, 
restoring its physiological properties. The capacity of PEA to modulate the protective responses 
during inflammation suggests that endogenous PEA may be part of the complex homeostatic 
apparatus controlling the basal threshold of inflammatory processes. For this reason, we aimed to 
study the effects of PEA in a rat model of AD and here, we provide the first in vivo evidence that 
PEA exerts simultaneously anti-inflammatory and neuroprotective effects. It is commonly 
accepted that Aβ deposits can be associated with local cell loss, oxidative stress, and neuroglial 
activation. Glia possesses endogenous homeostatic mechanisms/molecules that can be seriously 
affected as a result of tissue damage. As a consequence, activated glial cells lose their physiological 
functions and acquire a reactive phenotype, characterized by profound morphological and 
functional alterations (Verkhratsky and Butt, 2007). Among these, GFAP and S100β 
overexpression is the best-known hallmark of activated astrocytes (O'Callaghan and Sriram, 2005; 
Donato et al., 2013). In our model, we detected marked alteration of both these proteins. In fact, 
our results show that hippocampal astrocytes had significantly larger GFAP surface and express 
higher immunopositivity for S100β. Interestingly, PEA negatively modulated both GFAP and 
S100β transcription and expression, through its interaction with PPAR-α receptor. 
In this study, we highlighted the existence of an inflammatory state induced by Aβ(1-42) 
infusion, as detected by the increased expression and release of the some key regulators of 
inflammatory process. Remarkably, PEA reduced iNOS and COX-2 overexpression and the 
enhanced release of IL-1β and TNF-α. Overall, these findings suggest that PEA exerts a key role 
in regulating astrogliosis and important functional changes, which contribute to disease 
progression. 
Astrocytic cytokines may prompt the synthesis of acute-phase proteins such as APP 
(Blasko et al., 2000) increasing the production of Aβ, regulating the cytokine cycle itself (Griffin, 
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2011), and inducing neuronal death (Mrak, 2009) responsible for the neurodegenerative 
consequences. Astrocytes could be induced by pro-inflammatory stimuli to promote the expression 
of BACE1, thus increasing the conversion of APP into the neurotoxic insoluble Aβ which could, 
in turn, induce astrocytes to produce more inflammation-like glial responses (Luterman et al., 
2000; Rojo et al., 2008). Here, we demonstrate the ability of PEA to reduce the expression of 
BACE1 and APP, proteins directly involved in the amyloidogenic pathway. Collectively, these 
results identify PEA as a potential agent that is able to stop the detrimental cycle in which 
neuroinflammation and amyloidogenesis cooperate in sustaining the pathological state and the 
activation process of astrocytes. 
Besides Aβ accumulation in SPs, the accumulation of hyperphosphorylated tau proteins 
that yield to NFTs formation is another hallmark characteristic in AD brain. Many data indicate 
that inhibition of the canonical Wnt pathway contributes to the pathophysiology of 
neurodegenerative disorders. Previous studies (Caricasole et al., 2004) demonstrated the role for 
Dkk-1 in the mechanisms of Aβ toxicity. The ability of Aβ to induce the expression of Dkk-1 
causes an increased activity of Gsκ-3β resulting in the hyperphosphorylation of tau protein. Here, 
we show, for the first time in an in vivo model, the ability of PEA to restore the alteration in the 
Wnt pathway caused by Aβ(1-42) hippocampal infusion, and to reduce phosphorylated tau protein 
overexpression. These findings indicate an important neuroprotective function for this endogenous 
compound and, once again, highlight an important involvement of PPAR-α. To deeply investigate 
the effect of PEA on neuronal circuitry, we decided to perform analysis on a neuronal marker, 
MAP2. Our findings showed an important role of PEA in restoring MAP2 expression that resulted 
reduced after Aβ injection, confirming its neuroprotective effect. 
Finally, we decided to perform a MWM test to evaluate the effect of PEA on cognitive 
functioning. We found that Aβ(1-42)-infused rats did not present deficits in the acquisition and in 
the long-term retention of the task. This is of translational value because clinical observations 
report that general and profound learning dysfunctions do not occur in the early course of AD. 
Importantly, we found that Aβ(1-42) infusion in the dorsal hippocampus results in reversal learning 
deficits, which could be partially compared to working-like memory in humans (Morris, 2001; 
Savonenko et al., 2005). Impairment of working memory has been found to be a precocious marker 
for the future development of dementia (Sexton et al., 2010; Espinosa et al., 2013). Interestingly, 
PEA was able to restore the Aβ(1-42)-induced deficits, suggesting its capability to improve reversal 
learning deficits. 
The current investigation provides evidence that PEA, by activating PPAR-α, rescues 
altered molecular pathways as well as behavioral impairments that can mimic some early traits of 
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AD. Considering the extreme safety and tolerability of PEA in humans, our findings offer new 
opportunity in the already fruitless world of AD treatment.  
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SECTION III  
 
Effects of ultra-micronized palmitoylethanolamide in a triple transgenic mice model of AD  
 
INTRODUCTION 
 
Alzheimer’s disease (AD) is the most frequent cause of dementia in elderly that establishes 
a worldwide health problem. In the last year, around 47 million people worldwide were affected 
by dementia and, this number is expected to increase, plausibly reaching 131.5 million by 2050 
(Prince et al., 2015). AD is a chronic condition first described by Alois Alzheimer in 1907, mainly 
characterized by a progressive cognitive impairment (Alzheimer, 1907). It is classically 
characterized by the presence of amyloid plaques (SPs), caused by aggregation of beta-amyloid 
(Aβ) deposits, and neurofibrillary tangles (NFTs) composed by hyperphosphorylated microtubule-
binding protein tau (Selkoe, 2001). More recently, studies demonstrated that neuroinflammation 
is another key feature of the AD brains (McGeer and McGeer, 1999; Dandrea et al., 2001; Steardo 
Jr et al., 2015). Altogether, these elements contribute to neuronal cell death and synaptic 
dysfunction, and, ultimately, to learning impairment and memory loss. 
Neuroinflammation is guided by microglial cells, perivascular myeloid cells and reactive 
astrocytes surrounding SPs giving rise to the phenomenon of reactive gliosis (McGeer and 
McGeer, 2013; Osborn et al., 2016). This event has the initial aim of endogenous defence; 
however, the persistent activation establishes a self-fostering vicious cycle that contributes to AD 
progression (Steardo Jr et al., 2015). Reactive gliosis is characterized by the presence of reactive 
astrocytes that present an increase of glial fibrillary acid protein (GFAP) and hyperproduction of 
the neurotrophic factor S100β that, at higher non-physiological concentrations, becomes toxic. 
These activated cells become part of the inflammatory machinery, producing deleterious mediators 
like inducible nitric oxide synthase (iNOS), interleukin (IL)-1β and tumor necrosis factor (TNF)-
α under control of the transcription factor NF-κB (Heneka et al., 2010; Shih et al., 2015). In turn, 
these factors trigger astrogliosis acting in an autocrine manner and, at the same time, are 
responsible for the death of neighbouring neurons thanks to the paracrine action (Burda and 
Sofroniew, 2014). 
Tau protein is a microtubule-associated protein. In AD, it has been shown that tau is 
abnormally phosphorylated mainly by the glycogen synthase kinase-3β (Gsκ-3β), thus creating 
paired helical filaments (PHF-1) responsible for NFTs formation (Hanger et al., 1992). Gsκ-3β 
enzymatic activity is regulated by its own phosphorylation. Indeed, Tyr216 phosphorylation 
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increases its activity. On the contrary, Ser9 phosphorylation operated by Akt-pathway inhibits its 
activity (Jope et al., 2007). This pathway relates with neuronal survival, involving nuclear 
translocation of β-catenin by enhancing its transcriptional activity. Gsκ-3β inhibition, in addition 
to reducing tau phosphorylation, blocks β-catenin phosphorylation which can translocate into the 
nucleus and interact with DNA binding proteins inducing the transcription of pro-survival genes 
(Kim et al., 2013). By this manner, Akt/Gsκ-3β pathway promotes neuronal survival. 
Reactive gliosis and tau iperphosphorylation are events closely related to the presence of 
Aβ accumulation. Indeed, Aβ increase, especially the more toxic Aβ(1-42) fragment, caused by an 
intense activity of the amyloidogenic pathway, plays a pivotal role in the progression of the disease 
(O’Brien and Wong, 2011).  
At this point, we can affirm that each pathological event present in AD is somehow linked 
to all the others and, in order to better explore their relationship, the use of animal models is 
necessary. Among others, the triple transgenic model (3xTg-AD) of AD, harboring PS1M146V, 
APPSwe, and tauP301L transgenes (Oddo et al., 2003b), helps researchers to address this issue. 
These mice develop an age-dependent and progressive neuropathological phenotype that includes 
not only SPs and NFTs, with a penetrance of 100%, but even reactive gliosis in adulthood, 
detectable in the brain structures most impaired in AD, e.g. hippocampus, amygdala, and cerebral 
cortex (Oddo et al., 2003a; Griffith et al., 2016). Nowadays, this model is one of the most used in 
pharmacological research (Romano et al., 2014; Kosaraju et al., 2016; Sawmiller et al., 2016).  
With the aim of targeting neuroinflammation and neurodegeneration simultaneously, we decided 
to test the pharmacological effect of ultra-micronized palmitoylethanolamide (um-PEA) in 3xTg-
AD mice. PEA is an endogenous lipidic mediator, compound produced from palmitic acid and 
ethanolamine reaction, largely present in the central nervous system (CNS) mainly due to 
astrocytic production (Cadas et al., 1997). It has been demonstrated that exogenous PEA crosses 
the BBB and reaches therapeutic concentrations in the brain (Artamonov et al., 1999), despite the 
presence of enzymes responsible for its hydrolysis, N-acylethanolamine acid amide hydrolase 
(NAAA) and fatty acid amide hydrolase (FAAH). Recently, um-PEA, a crystalline form on 
micrometric size of PEA was tested. In this form, the compound has smaller particle size, making 
it a useful alternative to improve its bioavailability (Petrosino et al., 2016). Several studies already 
shown neuroprotective, anti-neuroinflammatory, and analgesic properties of PEA (Petrosino and 
Di Marzo, 2016). In addition, recent studies performed by our group already shown the therapeutic 
efficacy obtained by PEA treatment in both in vitro and in vivo models of AD (Scuderi et al., 2011, 
2012, 2014). 
51 
 
In this study, we wondered whether there are differences in efficacy of um-PEA treatment 
if administered before or after manifesting the pathological phenotype. For this reason, we started 
treatments at both 3 and 9 months of age.  
Here, we decided to further explore pharmacological um-PEA properties in 3x-Tg-AD mice, 
investigating some of the main pathways involved in AD pathogenesis such as neuroinflammation, 
Akt/Gsκ-3β and amyloidogenic pathways. Moreover, we tested um-PEA treatment at 2 different 
months of ages, 6 and 12, with the aim to understand if there is any difference in compound 
efficacy whenever the administration is done in the pre-symptomatic or symptomatic stage. 
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MATERIALS AND METHODS 
 
All procedures were conducted in conformity with the guidelines of the Italian Ministry of 
Health (D.L. 26/2014), and performed in compliance with the European Parliament directive 
2010/63/EU. 
 
Animals  
A total of 48 male mice were tasted. Homozygous 6- and 12-month-old 3xTg-AD mice 
were compared to wild-type littermates (Non-Tg). The 3xTg-AD mice expressing APPswe, 
PS1M146V, and tauP301L transgenes were genetically engineered by LaFerla and collaborators (Oddo, 
et al., 2003a; 2003b). Polymerase chain reaction (PCR) after tail biopsies has been performed to 
confirm genotypes. All animals were maintained in controlled conditions (12-h light/12-h dark 
cycle, temperature +22°C, humidity 50% - 60%, fresh food and water ad libitum).  
 
Chemicals 
Um-PEA was kindly provided by Epitech group srl (Padua, Italy). Innovative Research of 
America (Sarasota, Florida) have made the depot delivery system containing um-PEA or the 
proper vehicle (Model NF-141). Once subcutaneously implanted, these pellets released a constant 
amount of drugs for 30 days. The implant was replaced two times in order to cover the 90 days 
treatment.  
 
Study design 
Pellets were implanted subcutaneously to 3- and 9-month-old 3xTg-AD and Non-Tg mice. 
By this system, mice received 10mg/kg/die of um-PEA or vehicle for 90 days (Figure 1). Dosage 
and administration route were chosen according to our previous data and available literature (Costa 
et al. 2002; Grillo et al., 2013). 
Animals were first tested with behavioral studies, and subsequently sacrificed by 
decapitation to collect tissues. Hippocampi were isolated for western blotting and reverse 
transcriptase (RT)-PCR, and then stored at -80°C before analysis; whereas whole brains were 
frozen by 2-methylbutane and stored at -80°C before immunohistochemical analysis.  
In figure 1 the experimental design is reported. 
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Figure 1 Study design  
Schematic representation of the experimental design for both (a) 6-month-old and (b) 12-month-old 
Non-Tg and 3xTg-AD mice. 
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RNA isolation and RT-PCR  
Total RNA was extracted from emi-hippocampal homogenates using the NZY total RNA 
isolation kit (NZYTech, Lisboa, Portugal) according to the company’s datasheet. The total RNA 
concentration was measured by Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, 
MD, USA), so 1 µg of RNA was reversed transcribed to obtain cDNA by using oligo(dT) and 
random primers of the first-strand cDNA synthesis kit (NZYTech, Lisboa, Portugal). RNaseH 
from E. coli was used to digest RNA/DNA hybrids. All PCRs were performed using supreme 
NZYTaq DNA polymerase (NZYTech, Lisboa, Portugal) with specific primers (Sigma-Aldrich, 
Milan, Italy) for S100β (forward primer 5’-TAATGTGAGTGGCTGCGGAA-3’ and reverse 
primer 5’-CCTCACCAAGGGCTAAGCAG-3’), GFAP (forward primer 5’-
GGAGAGGGACAACTTTGCAC-3’ and reverse primer 5’-GCTCTAGGGACTCGTTCGTG-
3’), TNF-α (forward primer 5’-CAGCCGATGGGTTGTACCTT-3’ and reverse primer 5’-
CCGGACTCCGCAAAGTCTAA-3’), IL-1β (forward primer 5’-
GGACCCCAAAAGATGAAGGGC-3’ and reverse primer 5’-
GGAAAAGAAGGTGCTCATGTCC-3’), IL-10 (forward primer 5’-
GCCCTTTGCTATGGTGTCCT-3’ and reverse primer 5’-CTCTGAGCTGCTGCAGGAAT-3’), 
iNOS (forward primer 5’-CAAGCTGATGGTCAAGATCCAGAG-3’ and reverse primer 5’-
GTGCCCATGTACCAACCATTGAAG-3’). GAPDH (forward primer 5’-
GCTACACTGAGGACCAGGTTGTC-3’ reverse primer 5’-
CCATGTAGGCCATGAGGTCCAC-3’) was used as gene reference. 
 
Protein extraction and western blot analysis 
Emi-hippocampi were homogenized in ice-cold hypotonic lysis buffer (Tris/HCl pH 7.5 
50 mM, NaCl 150 mM, ethylenediaminetetraacetic acid (EDTA) 1 mM, 1% triton X-100, PMSF 
1 mM, aprotinin 10μg/ml, leupeptin 0.1mM (all from Sigma-Aldrich Milan, Italy) and incubated 
for 40 min at +4 °C. Proteins dephosphorylation has been avoided by adding 0.3 mg of phosphatise 
inhibitor cocktail per ml of lysis buffer. The homogenates were then centrifuged at 14000 rpm for 
30 minutes to discard membranes and keep aliquoted supernatant then stored at -80 °C waiting for 
the molecular processing. Bradford assay has been performed to calculate protein concentration in 
each sample in order to resolve an equal amount of proteins (50 μg) on 12% acrylamide SDS-
PAGE precast gels (Bio Rad Laboratories, Milan, Italy). Afterwards, proteins were transferred 
onto nitrocellulose membranes through a semidry system (Bio Rad Laboratories, Milan, Italy). 
Membranes were blocked for 1 h with either 5% w/v no-fat dry milk or bovine serum albumin 
(BSA) powders in tris-buffered saline-tween (TBS-T) 0.1% (Tecnochimica, Rome, Italy).  
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Overnight incubation at +4 °C on a shaker was performed with one of the following 
primary antibodies: rabbit anti-S100β (1:1000, Epitomics, Burlingame, CA, USA), rabbit anti-
GFAP (1:25000, Abcam, Cambridge, UK), rabbit anti-p[Ser536]-NF-κB p65 (1:2000, Cell 
Signaling, Danvers, MA, USA), rabbit anti-iNOS (1:8000, Sigma-Aldrich, Milan, Italy), rabbit 
anti-Gsκ-3β (1:1000, Cell Signaling, Danvers, MA, USA), rabbit anti-p[Ser9]-GSκ-3β (1:1000, 
Cell Signaling, Danvers, MA, USA), rabbit anti- p[Ser396]tau (1:1000, Thermo Fisher Scientific, 
Waltham, MA, USA), rabbit anti-Akt (1:500, Cell Signaling, Danvers, MA, USA), rabbit anti-
p[Thr308]-Akt (1:5000, Cell Signaling, Danvers, MA, USA), rabbit anti-β-catenin (1:200, Cell 
Signaling, Danvers, MA, USA), mouse anti-MAP2 (1:250, Novus Biologicals, Littleton, CO, 
USA), rabbit anti-APP (1:1000, Cell Signaling, Danvers, MA, USA), rabbit anti-BACE1 (1:1000, 
Cell Signaling, Danvers, MA, USA), mouse anti-β-amyloid (1:200, Santa Cruz, Dallas, TX, USA), 
rabbit anti-β-actin (1:1500, Santa Cruz, Dallas, TX, USA). 
After appropriate rinses in TBS-T 0.05%, membranes were incubated for 1h at room temperature 
with a specific secondary horseradish peroxidase (HRP)-conjugated antibody (HRP-conjugated 
goat anti-rabbit IgG, 1:10000 - 1:30000; HRP-conjugated goat anti-mouse, 1:10000; all from 
Jackson ImmunoResearch, Suffolk, UK) either in 5% w/v no-fat dry milk or BSA in TBS-T 0.1%. 
Immunocomplexes were detected by an ECL kit (GE Healthcare Life Sciences, Milan, Italy) and 
the signal obtained was quantified by ImageJ software after densitometric scanning of the X-ray 
films (GE Healthcare Life Sciences, Milan, Italy). 
 
Immunohistochemistry 
To evaluate GFAP and MAP2 levels and distribution, coronal slices (12 µm thickness) 
containing the hippocampal regions were collected by using a cryostat (Thermo Fisher Scientific, 
Waltham, MA, USA) and post-fixed with 4% paraformaldehyde in 0.1M phosphate buffer solution 
(PBS) (Tecnochimica, Rome, Italy) pH 7.4 for 7 minutes at +4C°. The slices were incubated with 
blocking solution (1% BSA, 0.25% triton X-100 in PBS 0.1M) for 2 h at room temperature and 
then incubated over night at +4 C° in 0.5% BSA, 0.25% triton X-100 TBS solution containing 
either rabbit anti-GFAP (1:1000, Abcam, Cambridge, UK) or mouse anti-MAP2 (1:250, Novus 
Biologicals, Littleton, CO, USA). The day after, sections were rinsed in PBS and then incubated 
with the proper secondary antibody (fluorescine-affinipure goat anti-rabbit IgG (H+L), 1:200; 
rhodamine-affinipure goat anti-mouse IgG (H+L), 1:300 - 1:400, Jackson ImmunoResearch, 
Suffolk, UK) and Hoecsth (1:75000, Sigma-Aldrich, Milan, Italy) in BSA 0.5%, triton X-100 
0.25% TBS, for 2 hours at room temperature. Slices were washed and coverslipped using 
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Fluoromount acqueous mounting medium (Sigma-Aldrich, Milan, Italy). Pictures were captured 
with a wide-field microscope (Eclipse E600; Nikon Instruments, Rome, Italy).  
Analysis were performed by ImageJ software and data expressed as a ratio of the difference 
between the mean of fluorescence signal and the background (ΔF), and the non-immunoreactive 
regions (F0). To prevent that any change in the fluorescent signal could be due to artifacts, the 
exposure gain and time were kept constant during all image acquisitions. 
 
Statistical Analysis 
Data were analyzed by two way-ANOVA followed by Bonferroni’s post-hoc multiple 
comparison test. Data are expressed as mean ± standard error of the mean (SEM). The level of 
statistical significance was p < 0.05. Statistical analysis was performed using GraphPad Prism 7 
software. 
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RESULTS 
 
um-PEA effect on reactive gliosis 
Reactive gliosis is one of the main pathological hallmarks of AD (Verkhratsky et al., 2010, 
2012), and is characterized by glial activation, commonly detected by S100β and GFAP 
overexpression, and neuroinflammation. Here, we tested the effect of chronic um-PEA treatment 
on reactive gliosis in the hippocampi of 6- and 12-month-old 3xTg-AD mice, by considering both 
astrocytic and inflammatory markers (Figure 2). 
We found that astrocytes from 6-month-old 3xTg-AD mice tended to be in an activated state as 
shown by a significant increase of S100β and GFAP transcripts (Figure 2a, b, c). This trend was 
not observed in the effective production of these proteins when tested by both western blot and 
immunofluorescence techniques (Figure 2h, i, l, o, q). um-PEA treatment was able to counteract 
GFAP, but not S100β, transcriptional increase (Figure 2a, b, c), without affecting their protein 
expression (Figure 2h, i, l, o, q). 
In 12-month-old mice, a strong decrease of S100β mRNA was observed in 3xTg-AD mice when 
compared with age-matched Non-Tg (Figure 2a, b). Despite this reduction, the total amount of the 
relative protein resulted unaffected (Figure 2h, i). Furthermore, in transgenic mice a significant 
decrease of both transcription and expression of GFAP was found (Figure 2a, c, h, l, p, q). At this 
age, um-PEA treatment significantly increased S100β mRNA, without affecting its protein 
expression (Figure 2a, b, h, i). In the same experimental conditions, um-PEA increased both 
transcription and translation of GFAP (Figure 2a, c, p, q).  
Interestingly, we recorded um-PEA action even in Non-Tg mice. We observed a reduced 
transcription of both astrocytic markers due to pharmacological treatment (Figure 2a, b, c). 
Inflammation is the other main feature of reactive gliosis, involving the activation of 
different sets of genes, most of them guided by NF-κB transcription factor (Zamanian et al, 2012). 
NF-κB is upstream for the transcription of several pro- and anti-inflammatory mediators, like 
iNOS enzyme, IL-1β, TNF-α, and IL-10 (Lawrence, 2009; Shih et al., 2015). In order to investigate 
um-PEA efficacy on inflammation, we studied NF-κB transactivation, occurring whenever its 
subunit p65 is phosphorylated in Ser536 (Jiang et al., 2003).  
We found that 6-month-old 3xTg-AD animals present an inflammatory state, proved by a 
statistically significant increase of p[Ser536]p65, when compared with Non-Tg littermates (Figure 
2h, m). It is reasonable that this is the cause of the significant increase of pro-inflammatory TNF-
α (Figure 2a, d) and IL-1β (Figure 2a, e) transcripts, and the significant decrease of IL-10 mRNA 
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(Figure 2a, f). In the transgenic model, at 6 months of age, the inflammatory state was confirmed 
by the significant increase of iNOS transcription and protein expression (Figure 2a, g, h, n). 
Chronic um-PEA treatment caused a marked decrease of p[Ser536]p65 subunit (Figure 2h, m), IL-
1β (Figure 2a, e), and iNOS mRNAs (Figure 2a, g) but did not affect TNF-α transcription (Figure 
2a, d). Moreover, um-PEA induced a significant transcriptional increase of the anti-inflammatory 
cytokine IL-10 (Figure 2a, f). 
Different results were obtained in aged mice. Indeed, by comparing 3xTg-AD and Non-Tg 
mice, in the former we observed significant differences only for IL-10 and iNOS mRNAs, which 
resulted increased and decreased, respectively (Figure 2a, f, g). Despite um-PEA up-regulated 
iNOS mRNA, treatment resulted in a significant reduction of the corresponding protein amount 
(Figure 2a, g, h, n).  
Notably, um-PEA treatment had a positive effect even in aged Non-Tg mice. We found that um-
PEA was able to significantly reduce p[Ser536]p65 expression (Figure 2h, m), and strongly induce 
IL-10 transcription (Figure 2a, f). These data agree with the notion that neuroinflammation occurs 
also in physiological aging (Gabuzda and Yankner, 2013), confirming PEA anti-inflammatory 
properties. 
Collectively, these results shown that 6-month-old 3xTg-AD mice present a mild astrocyte 
activation and an intense inflammatory status. By contrast, 12-month-old 3xTg-AD animals did 
not present reactive state neither neuroinflammation. The overall effect of um-PEA treatment was 
to stabilize the altered parameters related to reactive gliosis, bringing them to more physiological 
levels. 
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Figure 2 PEA effect on reactive gliosis in hippocampus of 3xTg-AD mice, both 6- and 12-
month-old 
(a) Rapresentative results obtained from RT-PCR for S100β, GFAP, TNF-α, IL-1β, IL-10, iNOS 
mRNAs, and (b-g) densitometric analysis of corresponding bands normalized with GAPDH. 
Results are express as percentage of control (Non-Tg/Veh groups). (h) Representative western 
blots for S100β, GFAP, p[Ser536]p65, iNOS proteins and (i-n) densitometric analyses normalized 
with β-actin used as loading control. Results are express as percentage of control (NonTg/Veh 
groups). (o-p) Rappresentative fluorescent photomicrographs of GFAP (green) staining in the CA1 
region of hippocampi at both 6 (o) and (p) 12 months of age, and (q) fluorescence analysis 
expressed as ΔF/F0. Nuclei were stained with DAPI (blue). Data are presented as means ± SEM 
and statistical analysis was performed by two-way ANOVA followed by Bonferroni multiple 
comparison test (* p < 0.05; ** p < 0.01; *** p < 0.001). Scale bar 10 um. 
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um-PEA role in tau phosphorylation and neuronal survival 
Tau protein is a microtubule-associated protein that allows microtubules assembly and 
stabilization according to its phosphorylation (Cleveland et al., 1997). Tau protein 
hyperphosphorylation results in the production of PHFs which, in turn, are responsible for NFTs 
creation. These structural modifications lead to neuronal dysfunction and cognitive impairments 
(Zhu et al., 2007). Several kinases add phosphate groups on tau specific amino acids. Among 
these, Gsκ-3β is one of the kinases mainly involved in the creation of NFTs (Engel et al., 2006). 
Its activity is regulated by a serine/threonine-specific protein kinase, known as Akt (Grimes and 
Jope, 2001). Akt/Gsκ-3β pathway is involved in the neuronal survival regulation by controlling 
the expression of β-catenin, that mediates pro-survival signals (Yuan et al., 2005). Activated Gsκ-
3β causes β-catenin ubiquitination and degradation (Aberle et al., 1997), resulting in neuronal 
death. This is patent in several neurological conditions, such as in AD (Zhang et al., 1998; De 
Ferrari and Inestrosa, 2000; Li et al., 2007a). 
Here, we tested um-PEA effectiveness on tau phosphorylation via Akt/Gsκ-3β pathway 
(Figure 3), and the subsequent effect on neuronal survival (Figure 4). 
We evaluated the expression of p[Thr308]Akt, the active form of this enzyme responsible of Gsκ-
3β inactivation through Ser9 phosphorylation (Jope et al., 2007), as well as tau protein damage 
through the amount of p[Ser396]tau. 
Despite no changes in the total Akt quantity (Figure 3a, b), we found a significant decrease of 
p[Thr308]Akt in 6-month-old 3xTg-AD mice in comparison with Non-Tg littermates (Figure 3a, 
c). Accordingly, although no difference in the total amount of Gsκ-3β kinases was detected (Figure 
3a, d), transgenic animals shown p[Ser9]Gsκ-3β reduction (Figure 3a, e). Lastly, we observed a 
significant p[Ser396]tau increase and a marked decrease in β-catenin expression in 3xTg-AD mice 
in comparison with age-matched Non-Tg (Figure 3a, f, g). 
um-PEA treatment was able to induce a global regulation of the Akt/Gsκ-3β pathway in 6-month-
old 3xTg-AD mice in comparison with Non-Tg. Indeed, we observed a significant increase of 
p[Thr308]Akt and p[Ser9]Gsκ-3β, resulting in a marked increase of β-catenin levels (Figure 3a, c, 
e, g), and decrease of p[Ser396]tau (Figure 3a, f).  
At 12 months of age, we observed a significant reduction of the inactive form of Gsκ-3β with the 
subsequent increase of p[Ser396]tau in 3xTg-AD mice when compared with Non-Tg littermates 
(Figure 3a, e, f). Interestingly, um-PEA chronic treatment strongly counteracted p[Ser396]tau 
development (Figure 3a, f). At this age, all other parameters were not affected by either genotype 
or treatment. 
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Figure 3 PEA effect on tau phosphorylation in hippocampus of 3xTg-AD mice both 6- and 12-
month-old 
(a) Representative western blots for Akt, p[Thr308]Akt, GSκ-3β, p[Ser9]GSκ-3β, p[Ser396]tau, β-
catenin and (b-h) densitometric analysis normalized to β-actin used as loading control. Results are 
express as percentage of control (Non-Tg/Veh groups). Data are presented as means ± SEM and 
statistical analysis was performed by two-way ANOVA followed by Bonferroni multiple comparison 
test (* p < 0.05; *** p < 0.001).  
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Since we detected marked alterations of Akt/Gsκ-3β pathway, we decided to investigate 
neuronal survival testing MAP2 expression (Figure 4). Results from western blot analyses did not 
show any difference among groups at both ages (Figure 4d, e). To deeper explore the different 
hippocampal areas, we performed additional immunofluorescence experiments. Obtained data 
revealed statistically significant differences only in the CA1 region. We found increased MAP2 
immunopositivity in 6- (but not in 12-) month-old 3xTg-AD mice in comparison with Non-Tg 
animals (Figure 4 a, b, c). The same set of experiments revealed that um-PEA administration 
promoted neuronal survival. Indeed, we detected increased MAP2 signal in 3xTg-AD mice at both 
ages, but only at 6 months of age in Non-Tg ones (Figure 4 a, b, c).  
In their entirety, these results indicate that transgenic mice show marked alterations in the 
Akt/Gsκ-3β pathway, especially at 6 months of age. However, these modifications seem to not be 
enough to cause neuronal death. The overall effect of um-PEA treatment was to stabilize the 
altered parameter related to Akt/Gsκ-3β pathway, and to promote neuronal survival in both 
genotypes. 
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Figure 4 PEA effect on neuronal survival in hippocampus of 3xTg-AD mice, both 6- and 12-
month-old 
Rappresentative fluorescent photomicrographs of MAP2 (red) staining in the CA1 region of 
hippocampi at both 6 (a) and (b) 12 months of age, and (c) fluorescence analysis expressed as 
ΔF/F0. Nuclei were stained with DAPI (blue). (d) Representative western blots for MAP2 and (e) 
densitometric analyses normalized with β-actin used as loading controls. Results are express as 
percentage of control (Non-Tg/Veh groups). Data are presented as means ± SEM and statistical 
analysis was performed by two-way ANOVA followed by Bonferroni multiple comparison test (* 
p < 0.05; ** p <0.01). Scale bar 100 um. 
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um-PEA action on the amyloidogenic pathway  
The amyloidogenic APP processing is the pathway mainly responsible for Aβ release 
(mostly Aβ(1-40) and Aβ(1-42)) and implies the involvement of β-secretase (BACE1) (O’Brien and 
Wong, 2011). 
In our model, we evaluated the expression of APP, BACE1, and Aβ(1-42) peptide, as well 
as the effect of um-PEA chronic treatment. 
6- and 12-month-old 3xTg-AD mice compared with Non-Tg littermates shown a statistically 
significant increase of APP and, despite no changes in BACE1 expression, they had a massive 
Aβ(1-42) amount (Figure 5). At both ages, chronic um-PEA treatment failed in inhibiting APP 
production (Figure 5a, b). Interestingly, um-PEA was able to strongly reduce Aβ(1-42) levels in both 
3xTg-AD and Non-Tg mice at 12 months of age (Figure 5a, d). 
Collectively, these results confirm an intense amyloidogenic pathway activity in 3xTg-AD 
mice, and um-PEA capability to greatly decrease Aβ(1-42) levels. 
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Figure 5 PEA effect on amyloidogenic pathway in hippocampus of 3xTg-AD mice both 6- 
and 12-month-old  
(a) Representative western blots for APP, BACE1 and Aβ(1-42) proteins and (b-d) densitometric 
analyses normalized to β-actin used as loading control. Results are express as percentage of control 
(Non-Tg/Veh groups). Data are presented as means ± SEM and statistical analysis was performed 
by two-way ANOVA followed by Bonferroni multiple comparison test (* p < 0.05; ** p < 0.01; 
*** p < 0.001). 
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DISCUSSION 
 
Here, we provide the first in vivo evidence about the anti-inflammatory and neuroprotective 
effects of a chronic um-PEA treatment in 3xTg-AD mice. Moreover, original and unique aspect 
of this study is the treatment schedule, designed to investigate both asymptomatic and frank stages 
of AD pathology. Current work increases knowledge about the molecular mechanisms involved 
in AD and suggests a potential new therapeutic approach. We comprehensively examined 
pathways underlying astrocytic activation, neuroinflammation, and neuronal integrity in 6- and 
12-month-old 3xTg-AD mice, relative to Non-Tg, receiving either um-PEA or vehicle for 3 
months. Our results clearly indicate that important molecular modifications occur already at early 
stages, and that um-PEA treatment is able to counteract most of them. 
Such results are of great interest since, to date, AD is one of the main public health challenges, 
and no efficacious treatments are available. The growing demand for new therapeutic tools has 
prompted researchers to better understand less explored AD hallmarks to manipulate them. In the 
last two decades, beside old and current pharmacological approaches to hit SPs and NFTs, other 
strategies aimed at controlling other aspects of this disorder, such as neuroinflammation.  
It has been known for a long time that PEA displays marked anti-inflammatory properties in 
peripheral inflammation models. Recently, its effectiveness has been also demonstrated in models 
of neurodegenerative disorders presenting inflammatory features, like AD, Parkinson's disease, 
and multiple sclerosis (D’agostino et al., 2012; Esposito et al. 2012; Scuderi et al., 2014; Rahimi 
et al., 2015). The recent availability of um-PEA, crystalline form of micrometric size that improves 
the pharmacokinetics and thus the bioavailability (Impellizzeri et al., 2014; Petrosino and Di 
Marzo, 2016), prompted us to test its anti-inflammatory and neuroprotective effects in a transgenic 
model of AD.  
Glia rapidly acts in response to several brain injuries, including Aβ deposits, undergoing important 
morpho-functional changes that can, in turn, influence disease course. Such modifications are 
intricate and heterogeneous, and can be crudely identified as hyperreactivity or atrophy (Rodríguez 
et al., 2009; Verkhratsky and Parpura, 2016). Moreover, a direct correlation has been established 
between glia activation and induction of pro-inflammatory pathways (Orre et al., 2014). In our 
model, we detected alterations of GFAP and S100β, the best-known markers of astrocytic 
activation, as well as of parameters related to neuroinflammation (i.e., NF-κB, iNOS, IL-1β, TNF-
α, and IL-10). Collected results highlighted that the scenario was completely different between the 
two ages. Indeed, 6-month-old 3xTg-AD mice displayed a mild astrocyte activation and an intense 
70 
 
inflammatory status. Notably, um-PEA revealed its ability to counteract both astrocyte activation 
and inflammation. Indeed, it significantly reduced GFAP mRNA and blocked NF-κB 
transactivation, thus reducing the transcription of IL-1β and iNOS. PEA action was also confirmed 
by the induction of the anti-inflammatory IL-10 cytokine. 
Differently, 12-month-old 3xTg-AD mice did not show any sign of neuroinflammation, as 
expected by the moderate astrocytic atrophy observed at this age. Indeed, transgenic animals 
exhibited lower GFAP and S100β levels when compared with age-matched Non-Tg. um-PEA 
treatment caused a marked increase of both S100β and GFAP in 3xTg-AD, but reduced these 
markers in Non-Tg. The effects of this compound even in old Non-Tg animals are crucial because 
astrocyte activation in aging is a well-documented phenomenon (Landfield et al., 1977; Yoshida 
et al., 1996). Our results suggest that, in both genotypes, um-PEA treatment regulates the 
expression of these proteins, bringing them to the same, likely optimal, levels. Therefore, the 
pharmacological treatment seems to counteract the negative effect of aging not only in 3xTg-AD, 
but even in Non-Tg mice, suggesting an important balancing role of this compound. 
It is now accepted that both astrocytic activation and atrophy simultaneously occur in AD 
brains, contributing to neuronal death (Rodríguez et al., 2009). Since our data shown both 
astrocytic behaviours, we decided to investigate Akt/Gsκ-3β pathway activation. Indeed, it is 
involved in the phosphorylation of tau proteins which are strictly connected to NFTs development, 
another key hallmark of AD brain. Here we show, for the first time in an in vivo model, um-PEA 
ability to prevent the alteration in the Akt/Gsκ-3β pathway observed in 6-month-old 3xTg-AD 
mice, and to reduce tau protein phosphorylation at both ages. The neuroprotective effects of um-
PEA were confirmed by fluorescence microscopic detection of MAP2, a structural neuronal 
marker. Our results highlighted a key role of um-PEA in increasing neuronal survival in 3xTg-AD 
mice at both ages. Surprisingly, this pro-survival effect was also observed in 6-month-old Non-Tg 
animals. 
By immunofluorescence analysis we observed that 6-month-old 3xTg-AD mice express more 
MAP2 in comparison with Non-Tg littermates. This curious result could be justified by the mild 
astrocytic activation observed at this age, whose primary goal is reparative (Myer et al., 2006; 
Burda and Sofroniew, 2014). It is possible to speculate that this reactive status has not yet reached 
levels such as to trigger deleterious processes, instead promotes reparative and pro-survival 
pathways that could support neurons. 
Beside NFTs formation, Aβ accumulation in SPs is another AD characteristic hallmark. It 
has been demonstrated that inflammation accelerates the development of AD phenotype, being 
responsible for the increment of the amyloidogenic pathway (Wozniak et al., 2007). Based on 
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current results about reactive gliosis, we explored the main elements involved in the pro-
amyloidogenic APP cleavage and the resulting expression of Aβ(1-42), one of the more toxic 
fragments. Since the presence of the APPswe transgene, we recorded an exacerbation of this protein 
in 3xTg-AD mice at both ages. Even if any alteration in BACE-1 level was recorded among all 
experimental groups, a >15-fold increase in Aβ(1-42) expression was observed comparing 3xTg-AD 
to Non-Tg mice. Our results demonstrated, for the first time, the ability of um-PEA to strongly 
reduce the expression of Aβ(1-42) in both genotypes at 12 months of age. um-PEA acted, once again, 
not only in 3xTg-AD, but even in aged Non-Tg animals, suggesting its important role in 
dampening aging in health and disease. 
The current investigation allows a better knowledge of pathology progression in 3xTg-AD 
mice and demonstrates the therapeutic potential of um-PEA in fighting the aging process, by 
exerting a combination of anti-inflammatory and neuroprotective effects. 
Although our results indicate that, in aged mice, um-PEA treatment caused regulatory 
effects on pathways mainly involved in AD pathology, more interesting data were obtained in 6-
month-old animals. Indeed, AD features of animals treated precociously with um-PEA (starting 
from 3 months of age, without any clinical sign of disease) seemed to be less pronounced, 
suggesting the benefit of starting drug treatment very early. It is noteworthy that PEA, by virtue 
of its high tolerability and safety also demonstrated in humans, could be suitable for long-term 
treatments that last years, as AD requires.  
In conclusion, current results show that the best way to counteract AD is probably starting 
the pharmacological treatment as soon as possible, pushing researchers to find diagnostic tools for 
a precocious disease detection. 
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SECTION IV  
 
High [K+]o induced LTP increases hippocampal CA1 dendritic spines area in mouse brain 
slices 
 
INTRODUCTION 
 
Synaptic plasticity represents the capability of synapses to strengthen or weaken as an 
adapting mechanism of the brain to react to external and internal stimuli (Malenka and Nicoll, 
1999). Long-term depression (LTD) and long-term potentiation (LTP) are two forms of plasticity 
that can last from minutes to hours. LTP has been first described in the rabbit hippocampus in 
1966 by Terje Lømo (Lømo, 1966) and then characterized as a specific synaptic response occurring 
after strong neuronal stimulations (Bliss and Lømo, 1973). LTP is considered to underlie the 
processes of learning and memory (Morris et al., 1986; Bliss and Collingridge, 1993; Malenka, 
1994; Martin et al., 2000; Gruart et al., 2006), thus explaining why hippocampal region has been 
the subject of LTP studies from decades. 
The LTP phenomenon requires a complex molecular cascade that can be activated in 
different regions and in different manners. The initial event starts from receptors activation by 
neurotransmitters and action potential propagation which in turn cause the release of secondary 
messengers that activate protein kinases (Stepan et al., 2015). Dendritic spines are the main 
structures involved in synaptic potentiation (Harris and Kater, 1994), although presynaptic sites 
are also implicated. Dendritic spines are rich in actin and thus morphologically highly dynamic. 
In response to LTP, they undergo shape and cytoskeletal remodeling and eventually increase their 
volume, features that are thought to be critical for potentiation (Yuste and Bonhoeffer, 2001). 
The LTP that takes place in the CA1 region of the hippocampus occurs as a result of 
postsynaptic N-methyl-D-aspartate receptors (NMDARs) activation (Collingridge et al., 1983; 
Harris et al., 1984). The opening of NMDARs channel is voltage-dependent and this is 
subordinated to the presence of extracellular Mg2+ (Mayer et al., 1984; Nowak et al., 1984). During 
normal transmission, glutamate released from presynaptic membrane binds both α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPARs) and NMDARs without 
inducing any potentiation because only AMPARs allow Na+ postsynaptic influx. Whenever 
depolarization takes place, Mg2+ detaches from the NMDARs channels thereby increasing Ca2+ 
and Na+ permeability of the postsynaptic membranes through this receptor (Malenka and Nicoll, 
1999). Ca2+ intake increases AMPARs conductance (via protein kinase) as well as the delivery 
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and/or clustering of the receptor within the postsynaptic plasma membrane (Malinow and 
Malenka, 2002) in order to mediate the transmission (Hayashi et al., 2000). The increase of Ca2+ 
in the dendritic spines is the actual event that triggers secondary messengers cascade allowing the 
long-lasting potentiation.  
Experimentally, it is possible to induce LTP in vitro and ex vivo in different manners: for 
instance, glutamate uncaging onto single spines (Matsuzaki et al., 2001) and 10 minutes treatment 
with 10 mM glycine (Musleh et al., 1997) (a NMDARs co-agonist) are two methods able to mimic 
the natural synaptic strengthen. Moreover, since the 80s it is known that a transient elevation of 
extracellular K+ concentration is sufficient to modulate neuronal membrane potential (Balestrino 
et al., 1986) and induce LTP in rat brain slices (Ballyk and Goh, 1992; Fleck et al., 1992; Harrison 
and Alger, 1993; Bernard et al., 1994; Roisin et al., 1997). This idea comes from the observation 
that repetitive stimulations at frequency commonly used to induce LTP also causes extracellular 
K+ increase (Krnjević et al., 1982; Poolos et al., 1987) that reaches a concentration of around 8 
mM in slices (Nicholson and Hounsgaard, 1983; Svoboda and Syková, 1991). The present study 
aimed at studying morphological changes in hippocampal CA1 spines after high [K+]o (20 mM)-
LTP induction by monitoring spines area. 
Previous studies performed by this lab confirmed the ability of high [K+]o (20mM) to 
induce LTP, achieving comparable effects obtained by high frequency stimulation (HFS) (data not 
published). Importantly, the concentration of K+ in the synaptic cleft after high [K+]o treatment 
was demonstrated to peak at around 8 mM, value consistent with that observed by direct HFS (data 
not published). The aim of this work is to show that 20 mM K+ aCSF is able to promote the volume 
increase of dendritic spines in the same conditions of K+-induced LTP. 
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MATERIALS AND METHODS 
 
Stereotaxic injection of rAAV5/CamKIIa-eYFP  
9 C57Bl/6 male mice 4 weeks old (Janvier) were housed on a 12-hour light-dark cycle, 
with ad libitum access to food and water. The day of the surgery, animals were deeply anesthetized 
with 1-1.5% isoflurane and placed in a stereotaxic frame. Short lasting analgesia was provided by 
injection of 0.05 mg/kg of buprenorphine. Local analgesia was provided by xylocaine (0.2 mg/mL) 
enough to cover the surface between the skin and the skull before the incision. A volume of 500 nL 
(5.2×1012 virus molecules/ml) at a flow rate of 100 nl/min of rAAV5/CamKIIa-eYFP was injected 
using the following coordinates: anterior-posterior (AP) -1.85 mm; medio-lateral (ML), 
±1.15 mm; and dorso-ventral (DV) -1.00 mm (relative to the bregma) (Figure 1). The needle was 
kept in the injection site for 8 minutes after the viral infusions and was slowly retracted thereafter. 
After the surgery, long lasting analgesia was provided by 5mg/kg of carprofen. The viral spreading 
took place for 3-4 weeks. 
 
Acute slices preparation 
Acute brain slices were prepared according to what has been previously described 
(Rangroo Thrane et al., 2013). Briefly, after 3-4 weeks of viral spreading, animals were mildly 
anesthetized with 1-1.5% isoflurane. After decapitation, the brains were rapidly removed and 
coronal slices (350 µm) obtained using a vibratome (Leica) in oxygenated (95% O2/5% CO2) cold 
modified Ringer solution composed of (in mM) sucrose 228.0, glucose 11.0, NaHCO3 26.0, 
MgSO4 7.0, KCl 2.5, NaH2PO4 1.0, CaCl2 0.5 (Schwartz et al., 2014) (Figure 1). 
The brain slices were incubated for 1 hour at +34°C and 30 minutes at room temperature 
(20-22°C) in continuously oxygenated (95% O2/5% CO2) artificial cerebrospinal fluid (aCSF) 
containing (in mM) NaCl 124.0, NaHCO3 26.0, glucose 11.0, KCl 2.5, CaCl2 2.5, MgCl2 1.3, 
NaH2PO4 1.0. 
 
20mM K+ LTP induction 
After recovery, slices were transferred to a slice chamber and continuously perfused at a 
rate of 2.5-3.5 ml/min with oxygenated aCSF. 
To induce high [K+]o-LTP, the perfusing aCSF was switched to 20mM K+ for 50 seconds 
and then returned to standard aCSF for the next 35 minutes (Figure 1). The 20mM K+ aCSF 
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solution had increased KCl and correspondingly reduced NaCl concentration to keep the 
osmolarity constant. 
 
2-photon imaging 
Dendritic spine imaging was carried out right before 20mM K+ perfusion, and 5, 15, 25 
and 35 minutes after high [K+]o-LTP induction. Image acquisition was performed by a Thorlabs 
2-photon microscope using a 20X (20X/1.00W) water immersion objective (Olympus). A laser 
(InSight DS+, Spectra-Physics) was used to excite YFP at 960nm and the emitted fluorescence 
was recorded using a 535/50 nm filter. 1024 × 1024 pixels was the image size; 20 frames (each 
resulting from 32 averages) were acquired for each time points, at depths between 70 and 150 µm 
from the surface of the slice (Figure 1). At these depths, the concentration of K+ after superfusion 
with 20 mM K+ has been measured to be around 8 mM (unpublished data from KU lab). 
 
Dendritic spine analysis  
A total of 267 spines distributed in 27 slices (~10 spines/slice) have been analyzed. ImageJ 
software was used to process and analyse images.  
In order to get a single image for each time point, the 20 frames obtained with each 
acquisition were co-registered and then averaged. The measurements of the spines area were 
obtained by manually drawing a line all around the perimeter of single spines for each time point 
and then measuring the inner area by ImageJ software. YFP signal was used as guide for dendritic 
spines area. 
 
Statistical analysis 
In order to get measurements in the same order of magnitude, all the results are expressed 
as percentage relative to the baseline (time -2’ 50''). Statistics were performed using the software 
GraphPad Prism 7 and differences were detected by one-way analysis of variance (ANOVA); 
multiple comparisons were performed using the Bonferroni’s post hoc test. 
Data are shown as mean ± SEM. Differences among mean values were considered 
statistically significant when p < 0.05. 
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Figure 1 Experimental procedure 
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RESULTS 
 
Dendritic spines behaviour that involves increasing volume is one of the main features of 
LTP (Kopec et al., 2006). To confirm that 20 mM [K+]o-LTP is able to induce the same outcome 
of HFS, we decided to monitor the dendritic spine areas projection since we obtained 2D images 
by averaging 20 frames for each time point.  
The YFP analysis of the total number of spines showed that there is a statistically 
significant increase of the areas that reaches statistical significance after 15 minutes (p < 0.01), 
and it keeps increasing up to 35 minutes (p < 0.001), time point in which maximum pick with an 
increment of 10.43% ± 1.63 have been registered (Figure 2A). The averaged value of changing 
during the 35 minutes resulted to be 7.40% ± 0.72. 
A closer look to the data revealed that there are different populations of dendrites behaving 
in different manners (Figure 2): 40.08% of the spines (Figure 2B green; Figure 2C) shows an 
increased area in each time point; 42.32% of the spine exhibited a “neutral” response (Figure 2G; 
Figure 2H) including spines (28.8%) with a trend in increasing their area (Figure 2B, yellow) and 
spines (13.48%) with a trend in decreasing their area (Figure 2B orange); 17.60% of the spines 
(Figure 2B red, Figure 2E) decreased their area. 
By calculating the average of the values for each group of spines, it has been estimated that 
the increase of the areas of the spines is 25.76% ± 0.99 for the former group (Figure 2D), while 
the decrease is around 18.8% ± 0.90 for the latter group (Figure 2F). 
Taken together these results show that high [K+]o-LTP induces different morphological 
changes of dendritic spines, but overall there is an increase of dendritic spines area. 
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Figure 2 Effect of 20 mM K+ on dendritic spines area  
(A) Measurement of area’s changes in the total number of dendritic spines. The dashed line 
represents the average value of changing during the 35 minutes after high [K+]o-LTP induction. 
(B) Representation of the different dendritic spines populations divided according to their 
behaviour in all time points: increase (green) represents all the spines that show an increased area 
at each time point after high [K+]o-LTP induction; trend increasing (yellow) represents all the 
spines that show an increase in at least 2 time points after high [K+]o-LTP induction; trend 
decreasing (orange) represents all the spines that show a decrease in 3 time points after high [K+]o-
LTP induction; decrease (red) represents all the spines that show a decreased area at each time 
point after high [K+]o-LTP induction. (C) Representative images (20X magnification, 17X zoom) 
of a dendritic spine increasing its area (YFP signal) after high [K+]o-LTP induction. (D) Behaviour 
of potentiated spines (n = 107) in 35 minutes after high [K+]o-LTP induction. The dashed line 
represents the average value of increase during the 35 minute. (E) Representative images (20X 
magnification, 17X zoom) of a dendritic spine decreasing its area (YFP signal) after high [K+]o-
LTP induction. (F) Behaviour of shrinking spines (n = 47) in 35 minutes after high [K+]o-LTP 
induction. The dashed line represents the averaged value of decrease during the 35 minutes after 
high [K+]o-LTP induction. (G) Representative images (20X magnification, 17X zoom) of a 
dendritic spine not changing its area (YFP signal) after high [K+]o-LTP induction. (H) Behaviour 
of neutral spines (n = 113) in 35 minutes after high [K+]o-LTP induction. 
Data are expressed as percentage of baseline (time -2’55'') as means ± SEM of 9 experiments (N 
= 9; ** p < 0.01; *** p < 0.001). Statistical analysis was performed by one-way ANOVA followed 
by Bonferroni’s multiple comparison test.  
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DISCUSSION 
 
The ability of an increased concentration of K+ to induce neuronal depolarization is a well-
established concept (Fleck et al., 1992) and recent data collected from this lab have shown that 
40-60s of treatment with 20mM K+ aCSF causes a significant increase in long lasting field 
excitatory postsynaptic potential (fEPSP) (data not published). This phenomenon seems to share 
the same mechanisms activated by HFS requiring NMDARs activation and Mg2+ detachment from 
the receptors, and AMPARs involvement in the CA1 hippocampal region (data not published). 
Moreover, this protocol have shown to trigger a comparable increase of [K+]o that is caused by 
HFS within the dendritic cleft (data not published); this confirmed the physiological importance 
of reaching a certain concentration of K+ in the dendritic cleft for the induction of LTP. A crucial 
feature underlying LTP is the increase of the dendritic spine volume that is observed during both 
early and late stages of potentiation (Kopec et al., 2006). 
In this study, we show that exposure of mice acute brain slices to 20 mM K+ for 50s causes 
an increase in dendritic spines areas as a consequence of high [K+]o-LTP induction (Figure 2A). 
Overall, we found an increase in dendritic spine volume when averaged across the entire 
population of synapses studied. This finding agrees with the report that fEPSP, a measure of 
“global” potentiation, also rises in the same conditions.  
Surprisingly, we found that there is a population of spines that do not react to the treatment, 
and another that reacts in the opposite manner, i.e. by decreasing their area. Thus, it is conceivable 
that the global potentiation registered by fEPSP masks those spines that, supposedly, are not 
potentiated or even depotentiated or silenced. 
The overall increase was statistically significant only starting from 15 minutes after high 
[K+]o-LTP induction, and continued up to 35 minutes (Figure 2A). However, it is clear that the 
increasing event is present already after 5 minutes, as shown in Figure 2D, but the effect is masked 
by the behaviour of depotentiated spines (Figure 2F). 
A possible explanation for our results is offered by the so-called “synaptic tagging 
hypothesis” first proposed in 1997 by Frey and Morris (Frey and Morris, 1997). Briefly, these 
authors proposed a model in which LTP induces the sequestration of a pool of proteins synthesis-
independent and mRNA (tags) in the surrounding space of the activated dendritic spine; this is one 
of the way in which early LTP can induce the long-lasting LTP (late-LTP). Recently, the Frey and 
Morris idea has been further developed by incorporating a mechanism of “competition and 
cooperation” among spines (Ramiro-Cortés et al., 2013). These authors suggest that, since 
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surrounding spines compete for the same pool of molecules, whenever a stimulus occurs, spines 
that have been stimulated stronger than others sequestrate the tags, thus winning the competition 
and being strengthened. The spines that lose the competition can even be removed. Competition 
can well explain our findings: it is indeed reasonable to suppose that, since the 20 mM perfused 
solution comes from one side of a chamber, and it has to reach the cells under the surface of the 
slice, some spines are potentiated sooner and stronger than others, although the final outcome is 
the induction of a global potentiation of CA1 region synapses. 
Altogether, these results provide further support for a role of physiological [K+]o increase 
in inducing LTP in excitatory synapses of the hippocampal CA1 region in mice slices. 
Despite the excellence of the results obtained, this study has potential for further 
improvement aimed at increasing the quality and statistical significance of our data. First of all, it 
will be necessary to confirm our results by comparing them with a control treatment, which means 
repeating the experiment in absence of high [K+]o-LTP. Later, to investigate the mechanism 
underlying our findings will be necessary. Specifically, to confirm NMDAR dependency the same 
experiments will be performed in presence of a NMDA antagonist, such as D-(-)-2-Amino-5-
phosphonopentanoic acid (AP5). 
Furthermore, it will be necessary to overcome some technical limitations to improve 
signals. We might use transgenic animal model, such as THY1-YFP mice, instead of AAV 
injection, in order to obtain a better signal-to-noise ratio. In this regard, it has to be pointed out 
that our choice was guided by the need to be consistent with previous electrophysiological results 
obtained from KU lab. Improving the image acquisition protocol could be another step. For 
instance, images could be captured without any averaging, and/or in small z-stacks, which would 
be helpful to compensate for small movements in z dimension and thus providing a way to follow 
the spines with more accuracy. The latter strategy could also be useful to estimate volume changes, 
in addition to area changes.  
In sight of the aforementioned arguments, further investigation will be needed. 
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